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Pattern recognition receptors (PRRs) sense unique and conserved structures 
common to many types of microorganisms and activate pro-inflammatory signaling 
cascades that are important for mounting effective immune responses, but aberrant 
regulation of PRR signaling can lead to autoimmunity.  Polymorphisms in NOD2, an 
intracellular PRR, are associated with increased risk of developing the inflammatory 
bowel disorder Crohn’s disease.  To gain insight into how NOD2 signaling is regulated, 
we performed a genome-wide siRNA screen in which NOD2-induced NF-κB activation 
was assessed using a luciferase reporter system.  Using this strategy, we identified and 
validated hundreds of novel regulators of the NOD2 and NF-κB signaling pathway, some 
of which were previously implicated in Crohn’s disease susceptibility.  By comparing our 
results with publicly available protein-protein interaction databases, we were able to 
visualize networks of genes, including the linear ubiquitin chain assembly complex, that 
are important for mediating NOD2-dependent responses.  Classically, PRRs are thought 
to function in differentiated cells to orchestrate inflammation, but recent evidence 
suggests that hematopoietic stem cells (HSCs), which maintain production of all blood 
cells throughout life, express PRRs and could be important for supporting immune 
responses during infection though the mechanisms underlying this function are unclear.  
We found that systemic infection of mice with the gram negative bacterium Escherichia 




HSC activity in spleen, indicative of extramedullary hematopoiesis.  Expansion of splenic 
HSCs was reduced in mice deficient for the PRR TLR4 or the adaptor protein RIPK2, 
which is required for NOD1 and NOD2 signaling, implicating PRRs in the regulation of 
HSCs during infection.  PRR signaling in radio-resistant cells was important for 
promoting progenitor expansion in spleen, suggesting an indirect mechanism.  We found 
that expansion of splenic HSCs was dependent on dual activation of NOD1 and TLR4 
and production of granulocyte-colony stimulating factor.  Altogether, these results 
provide a global view of the mechanisms that regulate PRR signaling and provide insight 



















Overview of the hematopoietic system 
 
The hematopoietic system can be broadly divided into two groups of cells, 
including red blood cells (RBCs; erythrocytes) whose main role is to transport oxygen 
throughout the body and white blood cells (WBCs; leukocytes), which defend the host 
against invading organisms and contribute to processes of wound healing.  WBCs are 
further subdivided into either innate or adaptive immune cells.  Leukocytes recognize 
infection or cellular damage by sensing and responding to conserved components of 
foreign organisms, termed pathogen associated molecular patterns (PAMPs), and 
alarmins, which comprise endogenous cellular structures that are typically shielded from 
immune recognition, but are released during injury and non-programmed cell death 
(Bianchi, 2007).  Recognition of harmful agents and subsequent interplay between 
different cell types via cytokines, chemokines and lipid mediators is essential for 
directing recruitment, activation, and resolution of the inflammatory response 
(Medzhitov, 2007).   
Many types of innate immune cells contribute to host defense, including antigen 
presenting cells (APCs) such as macrophages and dendritic cells (DC), megakaryocyte-




cells, eosinophils and basophils.  Although their roles are varied, each cell type can be 
classified by their general function.  At sites of infection or damage, PAMPs or alarmins 
are recognized by resident macrophages and DCs that initiate the immune response by 
secreting inflammatory cytokines and chemokines, engulfing invading microorganisms or 
damaged cells and processing ingested components for presentation to cells of the 
adaptive immune system (Aderem and Underhill, 1999; Soehnlein and Lindbom, 2010; 
Vyas et al., 2008).  Platelets initiate the coagulation cascade to form clots at sites of 
injury and coat bacteria to facilitate uptake by APCs (Projahn and Koenen, 2012; 
Verschoor et al., 2011).  NK cells kill host cells that attempt to evade the immune system 
such as tumorigenic cells and those infected with viruses, bacteria or parasites (Di Santo, 
2006).  Granulocytes limit the spread of microorganisms by exposing them to reactive 
oxygen species, proteolytic enzymes and anti-bacterial peptides present in their granules 
and by releasing cytokines to manipulate the inflammatory microenvironment and to 
prime adaptive immune responses (Geering et al., 2013; Pham, 2006; Stone et al., 2010).  
Together these innate immune cells form the first line of defense against potentially 
harmful organisms and agents.   
Cells of the innate immune system are considered innate because their genes 
encoding proteins utilized for host defense do not require rearrangement to function.  In 
contrast, cells of the adaptive immune system, including B-cells and T-cells, require 
rearrangements in genes encoding antibodies and T-cell receptors, respectively, to form 
functional proteins and to fully mature (Germain, 2002; Hardy and Hayakawa, 2001; 
Schatz and Ji, 2011).  Combinatorial rearrangement allows for the generation of a highly 




particular antigen is encountered.  Thus, the successful clearance of invading pathogens 
frequently involves cooperation between both branches of the immune system, with 
innate immune cells limiting the initial invasion, signaling infection and promoting cell 
recruitment, while adaptive immune cells generate pathogen specific and sustained 
responses.   
Both host defense and oxygen transport require extraordinary amounts of cellular 
proliferation and turnover.  Billions of damaged or defective RBCs are removed from 
circulation daily and must be replaced to sustain the body’s unyielding demand for 
oxygen (Higgins and Mahadevan, 2010).  Removal of potentially harmful stimuli such as 
invading bacteria, viruses, fungi, and damaged or tumorigenic cells requires expansion of 
immune populations, yet unrestricted cellular proliferation and inflammation can lead to 
cancer or autoimmunity (Barnes, 2008; de Visser et al., 2006; Geering et al., 2013; 
Michlewska et al., 2007; Rahman, 2011).  To support this massive requirement for new 
cells and to provide multiple levels of regulation, the hematopoietic system has evolved 
as a tiered hierarchy (Figure 1.1).   
At the base of the hematopoietic hierarchy are the innate and adaptive effector 
cells described above, which have limited replicative potential and are only capable of 
differentiating into specialized subsets.  Effector cells are immediately derived from 
lineage restricted progenitors, which differentiate into one or a few different effector cell 
types.  Lineage restricted progenitors arise from oligopotent progenitors with more 
relaxed differentiation capacity, such as common myeloid progenitors (CMPs) that give 
rise to erythrocytes, platelets, granulocytes and macrophages (Akashi et al., 2000) and 




et al., 1997).  Interestingly, DCs derive from CMPs and CLPs with equal potential, but 
because CMPs outnumber CLPs under steady state conditions, the majority of DCs arise 
from myeloid specific progenitors (Manz et al., 2001a; Manz et al., 2001b; Traver et al., 
2000).  A population of lymphoid-primed multipotent progenitors (LMPPs) has been 
described that gives rise to NKs, B-cells, T-cells, DCs, macrophages and granulocytes, 
but lacks the ability to produce erythrocytes and megakaryocytes (Adolfsson et al., 2005).  
The precursors of oligopotent progenitors are multipotent progenitors (MPPs) that by 
definition have the capability to produce all cells of the hematopoietic system, yet have a 
limited replicative lifespan ranging from a few weeks to a few months (Morrison and 
Weissman, 1994; Oguro et al., 2013).   
 At the zenith of the hematopoietic hierarchy lie hematopoietic stem cells. Like 
MPPs, HSCs have the capacity to give rise to all cells of the blood system, but in contrast 
to MPPs they possess the ability to self-renew, where cell division results in at least one 
daughter cell with equal differentiation potential as the parent.  Self-renewal divisions 
allow HSCs to maintain production of all hematopoietic cells over the lifespan of an 
organism (Orford and Scadden, 2008).  Impressively, HSCs from young mice are capable 
of surviving four or more rounds of serial transplantation before they die or differentiate 
(Allsopp et al., 2003).  This indicates that HSCs can support hematopoiesis nearly 
indefinitely and are able to survive multiple rounds of stress induced by transplantation, 
thereby outliving their original organism.  Consequently, therapies that utilize HSCs have 
proved beneficial in the clinic, where hematopoietic transplantation is used to treat a 
variety of disorders including severe combined immunodeficiency, leukemia, solid 




 In summary, the hematopoietic system contains multiple subsets of effector cells 
that have both unique and redundant functions in limiting the spread of infection, killing 
tumorigenic cells and supporting essential biological functions such as oxygen transport 
and wound healing.  Proper generation and regulation of effector cells is essential for 
health, as aberrant inflammation and cell proliferation can lead to autoimmunity and 
tumorigenesis.  Continuous and regulated production of effector cells is accomplished 
through a tiered system of highly proliferative progenitors that are maintained by a small 
pool of self-renewing HSCs.  Understanding how HSCs function under normal and 
pathologic conditions offers great promise for improving their use in treating human 
disease.   
 
Recognition of foreign organisms by PRRs 
 
In the perpetual conflict between macroscopic and microscopic organisms, a class 
of proteins termed pattern recognition receptors have evolved to recognize molecular 
motifs conserved in many types of microbes and trigger pro-inflammatory signaling 
cascades.  These PRRs include Toll-like receptors (TLRs), nucleotide-binding 
oligomerization domain-containing (NOD)-like receptors (NLRs), retinoic acid-inducible 
gene (RIG-I)-like receptors (RLRs) and C-type lectin receptors (CLRs).  RLRs dwell in 
the cytoplasm and sense viral-derived double-stranded RNA (Yoneyama and Fujita, 
2007).  CLRs are either secreted or reside in the plasma membrane where they recognize 
carbohydrates common to many types of pathogens (Geijtenbeek and Gringhuis, 2009).  




membranes that recognize components of bacterial and fungal cell wall, bacterial and 
viral DNA and RNA, and endogenous alarmins (Akira et al., 2006).  Once activated, 
TLRs recruit the adaptor proteins Myd88 (utilized by TLR1, 2, and 4-9) and TRIF 
(utilized by TLR3 and 4), which lead to signaling via nuclear factor-κB (NF-κB), 
mitogen activated protein kinases (MAPK) and interferon regulatory factor pathways that 
result in the transcription of genes important for inducing inflammation and killing 
invading organisms (Akira and Takeda, 2004).   
The founding members of the NLR family, NOD1 and NOD2, sense cleavage 
fragments of bacterial cell wall-derived peptidoglycan, whose minimal activating 
structures are meso-diaminopimelic acid (meso-DAP) and muramyl dipeptide (MDP), 
respectively (Chamaillard et al., 2003; Inohara et al., 1999; Inohara et al., 2003; Ogura et 
al., 2001b).  Signaling downstream of NOD1 and NOD2 is dependent on the adaptor 
protein receptor-interacting serine-threonine kinase 2 (RIPK2) and converges on NF-κB 
and MAPK pathways to promote inflammation (Girardin et al., 2001; Inohara et al., 
1999; Ogura et al., 2001b).  Dual stimulation with NLR and TLR agonists can result in 
the synergistic production of inflammatory cytokines and can promote maturation of 
antigen presenting cells, which is due in part to the upregulation of NOD1 and NOD2 
after TLR stimulation (Fritz et al., 2005; Tada et al., 2005; Takada et al., 2002; Takahashi 
et al., 2006).  Together, NLRs and TLRs can cooperate to initiate a robust immune 
response.   
Whereas clearance of invading organisms frequently relies on mounting an 
inflammatory response, excessive cytokine production and inflammation can damage 




following antigen encounter, is especially important at mucosal surfaces such as the 
digestive tract, where host cells are in close proximity to beneficial commensal bacteria 
(Steele et al., 2012).  Macrophages become tolerogenic to TLR signaling following initial 
stimulation with LPS, but maintain responsive to NLR agonists (Kim et al., 2008).  This 
provides a mechanism in which immune cells can effectively ignore signals emanating 
from commensals while maintaining vigilance against pathogens that attempt to breach 
the epithelial barrier.  Alteration of this delicate balance in the gut can predispose humans 
to autoimmune disorders such as Crohn’s disease (CD).     
 
Crohn’s disease and NOD2 
 
Inflammatory bowel disease (IBD), encompassing both CD and ulcerative colitis 
(UC), affects nearly 2 persons out of 1,000 in populations of European descent (Cho, 
2008). Patients suffering from IBD characteristically exhibit excessive destruction of the 
intestinal epithelium, which presents clinically as severe abdominal pain, bloody stool 
and excessive weight loss.  Inflammation in CD involves all layers of the bowel and is 
discontinuous, affecting isolated regions throughout the digestive tract while 
preferentially focusing in the terminal region of the small intestine.  In contrast, 
inflammatory lesions observed in UC involve only the luminal surface of the bowel and 
extend continuously from the rectum to the colon.  Treatment of IBD has classically 
involved the use of corticosteroids, which kills cells of the immune system, and more 
recently involves the use of antibodies that inhibit the inflammatory cytokine TNFα 




by surgical resection of the inflamed colon (Rokke et al., 2011).  As CD-associated 
inflammation can recur in multiple regions of the gastrointestinal tract, surgery is not 
curative for that condition (McLeod et al., 1997; Rutgeerts et al., 1990).   
Genome-wide association studies comparing IBD patients and healthy controls 
have linked inactivating mutations of NOD2 to CD, but not UC (Hampe et al., 2002; 
Hugot et al., 2001; Ogura et al., 2001a).  Mutations in both copies of the NOD2 gene 
confer a 20-40 fold enhanced susceptibility to CD (Hugot et al., 2001).  Still, biallelic 
inactivation of NOD2 does not invariably lead to CD and approximately 60% of CD 
patients do not have mutations in NOD2 (Cho and Abraham, 2007; Linde et al., 2003).  
This indicates that NOD2 plays an important role in preventing CD, but many other 
factors also contribute to CD susceptibility.  Indeed, polymorphisms in genes such as 
IL23R, IL12B, STAT3, JAK2 and the autophagy related gene ATG16L1 as well as 
smoking and a western diet are all risk factors for CD (Cho, 2008).  Moreover, mouse 
models of IBD require the presence of commensal bacteria, indicating that signals 
emanating from the gut microbiota are essential for promotion of CD (Elson et al., 2005).  
Altogether, CD is a multifactorial disorder that can affect all regions of the digestive tract 
and has a complex etiology involving both environmental and genetic components.    
Meta-analyses have revealed the existence of over 1000 independent CD 
susceptibility loci and the majority of these loci contain multiple genes of which the 
etiological factor is unknown (Barrett et al., 2008; Franke et al., 2010; Rivas et al., 2011).  
Given the importance of NOD2 signaling in CD, it is possible that proteins which 
regulate signal transduction downstream of NOD2 may also influence CD vulnerability 




genes within CD susceptibility loci are likely to be the causative factors.  Functional 
characterization of NOD2 regulators may also provide insight into the pathogenesis of 
CD and could elucidate novel targets for therapeutic intervention.  Interestingly, 
hematopoietic transplantation has emerged as a potential therapy for CD patients that are 
refractory to conventional treatments (Burt et al., 2010; Cassinotti et al., 2008; Hommes 
et al., 2011), so a better understanding of how infection and autoimmunity influence 
hematopoietic stem cell function may lead to improvements in current clinical practice.   
 
Prospective isolation of hematopoietic stem cells 
 
The concept that blood cells are derived from a small population of stem cells was 
first introduced by Till and McCulloch in 1961 based on their observation that 
transplantation of whole bone marrow (WBM) from untreated mice into irradiated mice 
resulted in the formation of nodal colonies in the spleens of recipients within ten days, 
which they termed colony forming unit-spleen (CFU-S) (Till and McCulloch, 1961).  
Supporting the idea that stem cells were responsible for the CFU-S activity, the number 
of transplanted bone marrow cells correlated linearly with the number of colonies formed 
and the colonies contained both undifferentiated and differentiated cells of clonal origin 
(Till and McCulloch, 1961).   
Later it was realized that most cells with CFU-S activity are not actually HSCs, 
but their more proliferative MPP progeny.  Yet it wasn’t until 1988 when the Weissman 
group used fluorescence activated cell sorting to fractionate whole bone marrow from 




irradiated recipients and contribute to myeloid and lymphoid lineages beyond six months 
that definitive HSCs could be isolated and studied with precision (Spangrude et al., 







, where Lineage (or Lin) represents a combination of 
surface markers present on differentiated blood cells that typically include CD3, B220, 
CD11b and TER119, which mark T-cells, B-cells, myeloid cells and erythrocytes, 
respectively.  To date, the gold standard for assessing HSC function in mice involves 
transplantation of donor cells (containing a putative HSC population) along with a fixed 
number of competitive whole bone marrow cells (containing a defined number of 
functional HSCs) into a conditioned (usually irradiated) recipient and assessing 
production of blood cells from both myeloid and lymphoid lineages over the course of 
four months, a time consistent with exhaustion of all non-HSCs in the donor graft (Purton 
and Scadden, 2007).  If HSCs in the test fraction are impaired in relation to competitor 
HSCs, they will either fail to engraft the recipient or exhibit diminished output of 
differentiated blood cells, indicative of a functional defect. 
Consistent with the finding that cKit mutant mice die perinatally due to 
hematopoietic defects, all HSCs have been shown to express the growth factor receptor 
cKit on their surface and require cKit signaling for survival (Bernstein et al., 1990; Ikuta 






 (LSK) population, which 
contains both HSCs and MPPs, based on expression of CD34, it was shown that 21% of 
single CD34
-/lo
 LSK from mouse bone marrow could provide long term multilineage 
reconstitution (LTMR) when co-injected with radioprotective cells, allowing extensive in 




Ema et al., 2000; Osawa et al., 1996).  Whereas the combination of CD34 and LSK are 
sufficient to robustly isolate functional HSCs by flow cytometry, these surface markers 
are not amenable to in situ staining and therefore are insufficient to visualize HSCs in 
their endogenous setting.   
In 2005, the Morrison group fractionated bone marrow based on positive or 
negative expression of the signaling lymphocyte activation molecule (SLAM) family 
members CD150 (Slamf1) and CD48 (Slamf2) and showed that all LTMR activity was 











 (to exclude contaminating megakaryocytes), 
the authors showed that 45% of single-sorted bone marrow cells and 33% of single-sorted 
spleen cells had LTMR activity (Kiel et al., 2005).  Moreover, using this combination of 
antibodies to stain sections of bone marrow, the authors were able to visualize putative 
HSCs throughout the bone marrow and frequently found these cells near vascular 
endothelium (Kiel et al., 2005).  Work from other labs has verified the utility of SLAM 
markers for staining HSCs under steady-state conditions and have revealed that the level 
of CD150 expression positively correlates with the ability of HSCs to self-renew (Morita 
et al., 2010; Weksberg et al., 2008).  Whether the SLAM markers accurately identify 
HSCs during periods of stress remains to be determined.   
 
Maintenance of hematopoietic stem cells in their niche 
 
In mice, the first definitive multilineage blood forming cells arise in the extra-




mesonepherous around E9.5 (Boisset and Robin, 2012; Mikkola and Orkin, 2006).  
Following their generation, embryonic HSCs migrate through the blood stream to the 
fetal liver, thymus and spleen and reside there just before birth, whereupon they transit to 
the bone marrow (Mazo et al., 2011).   In adults, the vast majority of HSCs are found in 
the bone marrow where they are surrounded by an interconnected system of supporting 
cells termed the “stem cell niche”.  Niche cells are responsible for supplying soluble 
and/or membrane bound factors that are important for maintaining HSC survival, 
quiescence and retention (Morrison and Spradling, 2008).  Quiescence, or exit from the 
cell cycle, is essential for the long term maintenance of HSCs, as deletion of genes that 
promote HSC quiescence leads to exhaustion of the stem cell pool and can result in 
lethality (Cheng et al., 2000; Takubo et al., 2010), while deletion of genes that inhibit 
HSC quiescence can improve HSC longevity and reconstitution potential (Yu et al., 
2006).  In the bone marrow, many cell types have been implicated as putative members 
of the stem cell niche including osteoblasts, osteoclasts, perivascular cells, mesenchymal 
progenitors, megakaryocytes, macrophages, neural cells, and endothelial cells but the 
necessity for each of these cell types in supporting HSC function is a subject of 
continuing debate (Kiel and Morrison, 2008; Park et al., 2012).   
For a cell or cell-derived factor to be considered part of the HSC niche, it must be 
demonstrated that some aspect of HSC biology is altered when the entity is removed.  
Table 1.1 summarizes growth factor and receptor pairs important for maintenance of 
adult HSCs within the bone marrow niche.  A prime example of an essential pair of niche 
components are the secreted and/or membrane bound protein Stem Cell Factor (SCF; Kit-




1992).  Mice deficient for SCF or cKit die near birth due to anemia, underscoring the 
importance of these genes in maintaining hematopoiesis (Bernstein et al., 1990; Broudy, 
1997).  To study the role of SCF in adult hematopoiesis, the cre/loxP system, in which a 
gene can be deleted by placing loxP sites around essential exons and expressing cre-
recombinase from a specific promoter to excise the “floxed” gene, was used to delete 
SCF after birth.  When SCF was deleted in all cells using a ubiquitously expressed 





LSK) was reduced more than 90% in the bone marrow and a reduction in HSC activity 
was confirmed by competitive transplantation (Ding et al., 2012).  Using cell-type-
specific deletion of SCF, it was shown that SCF from Tie2
+
 endothelial cells and Lepr
+
 
blood vessel-lining perivascular cells was required for HSC maintenance, whereas SCF 
from Vav1
+
 hematopoietic cells or Col2.3
+
 osteoblasts was not required (Ding et al., 
2012).  Thus, SCF is a bona-fide HSC niche factor and endothelial and perivascular cells 
are bona-fide members of the HSC niche.  
In addition to local growth factors, microenvironmental features such as hypoxia, 
or low oxygen tension, influence HSCs in their niche.  HSCs are enriched in regions of 
bone marrow that stain highly with pimonidazole, a compound that marks hypoxic cells 
(Parmar et al., 2007; Takubo et al., 2010; Varia et al., 1998).  Hypoxia inducible factor 1 
alpha (Hif1α) is a transcription factor that is upregulated when cells are exposed to 
hypoxia or inflammation and controls gene networks important for adaptation to low 
oxygen conditions such as upregulation of glycolytic enzymes and synthesis of 
angiogenic factors (Nizet and Johnson, 2009).  Using poly (I:C)-inducible Mx-1 cre to 








that following transplantation, Hif1α
Δ/Δ
 HSCs give rise to more progeny than wild type 
(WT) controls after 4 months, but Hif1α
Δ/Δ
 HSCs give rise to vastly reduced progeny 
when the cells were re-isolated and transplanted again, suggesting a loss of self-renewal 
(Takubo et al., 2010).  Consistent with this, in mice that received equal numbers of WT 
and Hif1α
f/f
 cells that were subsequently exposed to poly (I:C), Hif1α
Δ/Δ
 HSCs 
outcompeted WT HSCs after 4 months, but were outcompeted by WT HSCs after 11 
months (Takubo et al., 2010).  These results suggested that responsiveness to hypoxia by 
Hif1α is important for HSC maintenance long term.   
The authors went on to show that Hif1α
Δ/Δ
 HSCs are less quiescent, having a 
lower proportion of cells in G0 (Takubo et al., 2010).  Deletion of the E3 ubiquitin ligase 
von Hippel-Lindau (vHL
Δ/Δ
), which promotes the degradation of Hif1α, in hematopoietic 
cells resulted in the stabilization of Hif1α, expansion of the HSC pool and reduced HSC 
output (Takubo et al., 2010). This was due to decreased homing of vHL
Δ/Δ
 HSCs to the 
bone marrow after transplantation and increased quiescence, which would presumably 
limit the ability of HSCs to differentiate (Takubo et al., 2010).  The enhanced numbers 
and reduced output of vHL
Δ/Δ





deficient HSCs, indicating that the effects of vHL deletion on HSC quiescence and 
function were Hif1α dependent (Takubo et al., 2010).  Altogether, these results indicate 
that precise control of Hif1α levels in HSCs is required to avoid inescapable quiescence 
or exhaustion.  
These and other studies have made it clear that maintenance of HSCs within their 
bone marrow niche involves a complex interplay between extracellular factors, 




In general, any phenomenon that alters the bone marrow is likely to either directly or 
indirectly affect the HSCs within it.  Therefore, it is important to view alterations in HSC 
activity not only as consequence of changes within HSCs themselves, but also as a 
function of their local surroundings.  As I will discuss in the following sections, retention 
of HSCs within the bone marrow is also an important feature and manipulation of the 
bone marrow niche can result in egress of HSCs to the periphery.  
 
Localization and migration of hematopoietic stem cells 
 
Trafficking to the bone marrow in later stages of embryogenesis and residency 
within the bone marrow during adulthood is crucial for proper maintenance of HSCs.  
Table 1.2 summarizes factors that contribute to the localization and retention of adult 
HSCs in the murine bone marrow niche.  The first indication that a chemokine/receptor 
pair was important for HSC function came from mice constitutionally deficient in 
CXCL12 (also known as stromal derived factor-1; Sdf-1) or its g-protein coupled 
receptor CXCR4.  Mice lacking either CXCL12 or CXCR4 have nearly identical 
deficiencies in B-cell development during embryogenesis and B-cell and myeloid 
development during adulthood that correlates with massively reduced numbers of colony 
forming units in the bone marrow of these mice (Ma et al., 1998; Nagasawa et al., 1996; 
Zou et al., 1998).  To assess a role for CXCR4 in adult HSCs and to circumvent 
limitations associated with reduced bone marrow homing, CXCR4 was conditionally 
deleted from adult hematopoietic cells using poly (I:C)-inducible Mx-1 cre, which 




HSCs from these mice also exhibited reduced function, a feature that was shown to be 
cell autonomous by transplanting CXCR4
fl/fl
 cells along with WT cells and then deleting 
CXCR4, which resulted in the WT HSCs outcompeting those that lacked the receptor 
(Sugiyama et al., 2006).  Complimenting these findings, two separate groups 
conditionally deleted CXCL12 from Tie2
+
 endothelial cells or Prx-1
+
 mesenchymal 
progenitors and observed a reduced frequency and function of HSCs in the bone marrow 
(Ding and Morrison, 2013; Greenbaum et al., 2013).  Together, these results indicate that 
CXCL12 production from endothelial cells and mesenchymal progenitors within the bone 
marrow niche promote the retention of CXCR4-expressing HSCs during adulthood and 
that retention of adult HSCs within the bone marrow is essential for their optimal 
function.    
It has been known for some time that hematopoietic stem and progenitors 
(HSPCs) are present in the blood of adult mice (Dorie et al., 1979; Goodman and 
Hodgson, 1962).  To study physiologic trafficking of adult HSCs, some groups have 
utilized parabiosis studies, in which the circulatory systems of two genetically 
distinguishable mice are surgically linked.  Unlike competitive transplantation assays, 
where HSCs within the recipient mouse are killed by lethal irradiation in order to open 
niches for the donor HSCs to freely engraft, parabiosis assays test the ability of HSCs to 
migrate from one mouse, through the blood stream, to the conjoined mouse and compete 
with endogenous HSCs for residency in their niches.  When congenic mice were linked 
for 10 days to allow for normalization of their circulatory systems followed by surgical 
separation and sacrifice after five months, it was shown that about 1 to 5% of HSCs had 




beyond five months (Wright et al., 2001).  This demonstrated that a small fraction of 
adult HSCs regularly traffic through the blood stream and can compete for available 
niches.  More recently, functional HSCs have been isolated from lymphatic ducts, 
indicating that in addition to trafficking through the blood, HSCs transit through 
peripheral tissues and have the potential to contribute to local cell production at sites of 
inflammation (Massberg et al., 2007). 
 What processes control the physiologic release of HSCs from the bone marrow?  
Circadian rhythms integrate signals from light/dark cycles to control gene expression in 
nearly all tissues and are important for regulating energy utilization and controlling 
bodily processes such as preparing for food intake (Levi and Schibler, 2007).  Both 
HSPCs and HSCs exhibit rhythmic release from the bone marrow that parallels regular 
light-dark cycles and requires the essential clock gene Bmal-1 (Mendez-Ferrer et al., 
2008).  Surgical denervation or lack of the beta3 adrenergic receptor also disrupted the 
rhythmic egress of HSPCs to the blood stream and this was largely dependent on cyclic 
downregulation of CXCL12 within the bone marrow (Mendez-Ferrer et al., 2008).  While 
multiple facets of the niche influence retention of adult HSCs within bone marrow, the 
CXCL12/CXCR4 signaling axis appears to be the most dominant.   
 
A splenic reservoir of hematopoietic stem cells exists in adult mice 
 
The spleen is a multi-functional organ that simultaneously serves as a site for 
phagocytosis of defective erythrocytes, participates in erythropoiesis and acts as a 




adaptive immune system (de Porto et al., 2010).  Splenectomized mice and humans are 
viable, but suffer an enhanced susceptibility to encapsulated bacteria such as 
Streptococcus pneumonia due to a lack of innate B-cells (B-1a), which produce natural 
antibodies targeting capsular polysaccharides and require the spleen for persistence and 
antibody generation (Baumgarth, 2011; Kruetzmann et al., 2003; Wardemann et al., 
2002).  The spleen is also a reservoir for myeloid progenitors that can be recruited to sites 
of injury and aid in wound healing (Leuschner et al., 2012; Swirski et al., 2009).  During 
periods of stress, the spleen can act as a site of extramedullary hematopoiesis (O'Malley 
et al., 2005).  As noted in previous sections, HSCs can be isolated from murine spleen at 
later stages of embryogenesis and into adulthood, but their characteristics are less well 
defined as compared to bone marrow HSCs.   
Work from the Nakauchi group has provided the most detailed characterization of 
adult splenic HSCs under steady-state conditions.  When equal numbers of WBM or 
splenocytes were mixed with competitor bone marrow and transplanted, it was shown 
that splenic HSCs are approximately 15-fold less frequent than bone marrow HSCs on a 
percent basis (Morita et al., 2011).  By competitively transplanting single HSCs, defined 
as CD34
-/lo
 LSK, from bone marrow or spleen, the authors found no difference in the 
ability of these cells to repopulate recipient mice long term, indicating no inherent 
functional defects in splenic HSCs (Morita et al., 2011).  Importantly, the authors 
observed that CD34
-/lo
 LSK from the spleen were nearly twice as proliferative as their 
bone marrow counterparts and this enhanced rate of proliferation was determined by the 
tissue itself, as bone marrow-derived CD34
-/lo
 LSK that were transplanted into irradiated 




those which homed back to bone marrow (Morita et al., 2011).  This suggested that the 
splenic microenvironment drives a greater percentage of CD34
-/lo
 LSK to proliferate 
regardless of their previous origin.   
Perhaps the most interesting finding came from parabiosis studies, where the 
circulatory systems of two mice are linked.  After 7 weeks of parabiosis, the percentage 
of partner-derived circulating blood cells was approximately 50%, which is expected 
given unimpeded trafficking between each mouse (Morita et al., 2011).  By comparison, 
less than 15% of CD34
-/lo
 LSK in the bone marrow and spleen were derived from the 
adjoined partner (Morita et al., 2011).  This indicated that while cells in the blood stream 
had free access between each mouse, the majority of CD34
-/lo
 LSK in bone marrow and 
spleen remained in their original niche throughout the 7 week experiment.  Thus, under 
steady-state conditions there exists a small population of resident splenic HSCs that are 
more proliferative yet functionally comparable to bone marrow resident HSCs.  Whether 
resident splenic HSCs contribute to immune responses during infection is unknown.  
 
Transplantation and mobilization of hematopoietic stem and progenitors 
 
 While studies in the mouse have proved useful to dissect mechanisms underlying 
the regulation of HSCs in their niche, ultimately it will be necessary to translate this 
knowledge into improved therapies for humans.  Often, the goal of clinical hematopoietic 
transplantation therapies is to ablate the patient’s hematopoietic system, which might 
contain mutations that have led to cancer, autoimmunity, or lack of a particular 




contain the deleterious mutation and will faithfully recapitulate all cells of the 
hematopoietic system throughout the patient’s lifetime.  Many factors can influence the 
outcome of hematopoietic transplantation.  In particular, the source of donor cells, the 
disease status of the recipient and the conditioning regimen used to ablate the offending 
hematopoietic cells can dictate the speed and success of engraftment as well as the risk of 
subsequent disease (summarized in Figure 1.2) (Arai and Klingemann, 2003; Myers and 
Davies, 2009).  HSCs isolated from different sources offer characteristic benefits and 
limitations.  
There are three main sources of donor HSCs, including those isolated from 
umbilical cord blood, bone marrow, or peripheral blood following mobilization, which 
describes the induced migration of a cell population from the bone marrow to the blood 
stream.  Umbilical cord blood is saved at birth and is used in the same individual or 
matched recipient later in life; this is associated with lower occurrences of graft-versus-
host disease (GVHD), a condition in which the transplanted hematopoietic cells attack 
recipient cells due to antigen incompatibilities. However, umbilical cord blood 
transplantations are frequently associated with graft failure because of lower numbers of 
HSCs in the umbilical cord (Gluckman et al., 2001; Wagner et al., 2002).  Bone marrow 
is a rich source of HSCs, but isolation requires a painful procedure and hematopoietic 
reconstitution can be slower, resulting in an enhanced risk of bacterial infections and a 
requirement for more platelet transfusions (Arai and Klingemann, 2003).  By comparison, 
mobilization and isolation of HSCs from peripheral blood is relatively well tolerated by 
donors and results in faster hematopoietic reconstitution, fewer instances of bacteremia 




studies have shown that peripheral blood transplants are more likely than bone marrow 
transplants to result in chronic GVHD and systemic fungal or viral infections (Anderson 
et al., 2003; Schmitz et al., 2006).  While mobilized HSCs have become the preferred 
source for hematopoietic transplantation (To et al., 2011), it is debatable whether the 
short term benefits outweigh the long term risks.  A better understanding of the 
mechanisms that promote mobilization should lead to improvements in our ability to 
harvest HSCs and to mitigate harmful side effects.   
Though many cytokines, niche-disrupting agents and stress-inducing phenomenon 
can induce the mobilization of HSPCs (summarized in Table 1.3), granulocyte-colony 
stimulating factor (G-CSF) is the mobilizing agent of choice for autologous and 
allogeneic transplantation, since it is well tolerated and efficacious in the majority of 
hematopoietic donors (To et al., 2011).  Even so, approximately 5-30% of donors fail to 
mobilize sufficient numbers of HSCs for transplantation following G-CSF treatment and 
mobilization failure is correlated with increased age, prior exposure to cytotoxic drugs 
and genetic polymorphisms in critical niche components (Bogunia-Kubik et al., 2009; 
Hill et al., 2011; Hosing et al., 2009; Kumar et al., 2009; Martin-Antonio et al., 2011).  
Recently, the CXCR4 antagonist AMD3100 has been successfully used in many patients 
that fail to mobilize with G-CSF alone (Calandra et al., 2008; Liles et al., 2003).  While 
G-CSF treatment is associated with downregulation of CXCL12 in the bone marrow, 
mobilization of HSPCs with G-CSF and AMD3100 is synergistic, indicating that G-CSF 
promotes mobilization through both CXCL12/CXCR4 dependent and independent 
mechanisms (Broxmeyer et al., 2005; Flomenberg et al., 2005; Petit et al., 2002).  These 




macrophages and osteoblasts and also may involve the chemotactic lipid mediator 
sphingosine-1-phosphate (Christopher et al., 2011; Golan et al., 2012; Juarez et al., 2012; 
Katayama et al., 2006; Winkler et al., 2012; Winkler et al., 2010).  Mobilization is an 
effective tool for harvesting clinically useful preparations of HSCs, but gaps in our 
knowledge still exist about how and why mobilizing agents work.   
Hematopoietic transplantation is an attractive treatment for many diseases in 
which no other cure exists.  Mobilization with G-CSF is a safe and effective alternative to 
harvesting HSCs directly from bone marrow, yet the enhanced risk of delayed infection 
and chronic GVHD in transplant recipients indicates that complimentary strategies to 
limit adverse outcomes are needed.  The generation of AMD3100 and its growing clinical 
usage illustrates that identifying components of the HSC niche can be translated into 
better mobilization therapies. While procedures to mobilize HSCs have improved over 
the past decades, a subset of donors still fail to mobilize with dual administration of G-
CSF and AMD3100 (To et al., 2011).  Thus, the clinical community would benefit from a 
more comprehensive understanding of the mechanisms that facilitate HSC mobilization.   
There are many outstanding questions concerning how PRR signaling is 
controlled and how PRR activation influences the hematopoietic system.  The goal of 
Chapter II will be to identify novel regulators of the NOD2 and NF-κB signaling 
pathways.  This will be accomplished by performing an unbiased genome-wide siRNA 
screen in cells that express human NOD2 and an NF-κB reporter gene.  The goal of 
Chapter III will be to understand how bacterial infection affects the localization and 
function of HSCs and to determine which signaling pathways are responsible for these 




by analysis of the number and function of HSCs in wild type and knockout mice using 
flow cytometry and competitive transplantation assays.  Finally, in Chapter IV, I will 











































Table 1.1  Growth factor and receptor pairs important for maintenance of adult HSCs in mice 
Gene Effect on fetal HSCs Effect on adult HSCs References 
    
Stem Cell 
Factor (SCF) 
 Required for HSC 
maintenance in fetal 
liver (FL) 
 KO is embryonic lethal 
(hematopoietic defects) 
 Important for HSC 
maintenance in BM 
 Conditional KO has 
massive reduction in BM 
HSCs 




    
cKit  Required for HSC 
maintenance in FL 
 KO is embryonic lethal 
(hematopoietic defects) 
 Important for HSC 
maintenance in BM 
 Blocking antibody allows 
HSC engraftment in 
absence of irradiation 
(Czechowicz 





    
Thrombopoietin 
(THPO) 
 KO have enhanced 
LSK in FL 
 Functional requirement 
unknown 
 Important for promoting 
HSC quiescence and 
maintenance in BM 
 KO exhibit enhanced 
cycling, reduced HSCs in 
bone marrow 
(Qian et al., 
2007) 
    
cMPL  KO have enhanced 
LSK in FL 
 Functional requirement 
unknown 
 Important for promoting 
HSC quiescence and 
maintenance in BM 
 KO have reduced LSK in 
BM 
 Blocking antibody reduces 
quiescent HSC and allows 
HSC engraftment in 
absence of irradiation 




    
Angiopoietin 1 
(Ang1) 
 KO are embryonic 
lethal (vasculogenesis 
defects) 
 Functional requirement 
unknown 
 Addition in vitro promotes 
HSC quiescence and 
maintenance 
(Arai et al., 
2004; Suri et 
al., 1996) 
    
Tie2  KO are embryonic 
lethal (vasculogenesis 
defects) 
 KO have normal fetal 
hematopoiesis  
 Important for maintenance 
 KO FL HSCs are 

























Table 1.2  Regulators of HSC localization in murine bone marrow  
Gene Effect on fetal HSCs Effect on adult HSCs References 
    
CXCL12  
(Sdf-1) 
 Important for transition 
to BM  
 KO have impaired 
engraftment in fetal BM 
(extrinsic) 
 Important for BM 
retention and 
maintenance 
 Conditional KO have 
reduced HSCs in BM 






et al., 2013) 
    
CXCR4  Important for transition 
to BM 
 KO have impaired 
engraftment in fetal BM 
(intrinsic) 
 Important for BM 
retention and 
maintenance 
 Conditional KO have 
reduced HSCs in BM and 
increased cycling 
(Sugiyama 
et al., 2006; 
Zou et al., 
1998) 




 Important for transition 
to BM 
 KO have impaired 
engraftment in fetal BM 
(intrinsic) 
 KO is perinatally lethal 
(hypercalcemia) 
 KO FL HSCs are at a 
competitive disadvantage 
in adult recipients and do 









 unknown  Rhythmic entry and exit 
from bone marrow to 
blood is disrupted in KO 
(extrinsic, dependent on 
CXCL12) 
(Mendez-








Table 1.3  Stimuli capable of inducing HSPC mobilization 
Category Stimuli References 
   
Cytokines/Chemokines  G-CSF, GM-CSF, Flt3-L, 
CXCL2 (Gro-β), IL-1, IL-8, 
VEGF, CXCL12, SCF 
 
(Duhrsen et al., 1988; Fibbe et al., 
1992; Fukuda et al., 2007; Hattori et 
al., 2001; Kollet et al., 2006; Liu et 
al., 1997; Molineux et al., 1991; 
Socinski et al., 1988) 
 
    
Niche-disrupting 
agents 
 AMD3100 (CXCR4 antagonist), 
proteases, α-integrin Ab, α-
selectin Ab, α-VLA4 Ab 
 
(Craddock et al., 1997; Frenette and 
Weiss, 2000; Liles et al., 2003; 
Papayannopoulou et al., 2001; Vos 
et al., 1972) 
   
Stress-inducing 
phenomena 
 Bleeding, exercise, 
chemotherapy, zymosan, LPS 
(Barrett et al., 1978; Cheshier et al., 
2007; Richman et al., 1976; Vos et 






A Genome-Wide siRNA Screen Reveals Positive and Negative Regulators of the 




The cytoplasmic receptor NOD2 senses peptidoglycan fragments and triggers host 
defense pathways that lead to inflammatory immune responses. Dysregulation of NOD2 
signaling is associated with inflammatory diseases, such as Crohn’s disease. We used a 
genome-wide, small interfering RNA (siRNA) screen to identify regulators of the NOD2 
signaling pathway. Several genes associated with Crohn’s disease risk were identified in 
the screen, supporting a role for NOD2 and NF-κB pathways in the pathogenesis of 
Crohn’s disease. A comparison of hits from this screen with other “omics” data sets 
revealed interconnected networks of genes implicated in NF-κB signaling. Secondary 
assays, including the measurement of interleukin-8 secretion, served to validate many of 
the regulators. Knockdown of putative regulators in HEK293 cells followed by 
stimulation with tumor necrosis factor  revealed that most of the genes identified were 
general regulators of NF-κB signaling. Overall, the genes identified here provide a 
resource to facilitate the elucidation of the molecular mechanisms that regulate NOD2- 







To combat microbial infections, mammals mount a sophisticated immune 
response. Initial recognition of microorganisms by the innate immune system is mediated 
by various host-encoded pattern recognition receptors (PRRs). In many cases, PRRs 
stimulate both antimicrobial and pro-inflammatory responses. The nucleotide-binding 
oligomerization domain (NOD)-like receptor family of intracellular PRRs consists of 
multidomain scaffolding proteins, many of which are dysregulated in inflammatory 
diseases (Chen et al., 2009). NOD2 is found in various cell types, including monocytes 
and intestinal epithelial cells, and it is capable of sensing bacterial peptidoglycan 
fragments containing muramyl dipeptide (MDP) (Girardin et al., 2003; Inohara et al., 
2003). Upon sensing MDP, NOD2 undergoes a conformational change that leads to the 
recruitment of receptor-interacting protein serine-threonine kinase 2 (RIPK2), a step that 
is essential for the activation of downstream signaling (Kobayashi et al., 2002). 
Subsequently, Lys
63
-linked poly-ubiquitination of RIPK2 and nuclear factor κB (NF-κB) 
essential modulator (NEMO), a regulatory subunit of the inhibitor of κB (IκB) kinase 
(IKK) complex, leads to the recruitment of transforming growth factor–β (TGF-β)-
activating kinase 1 (TAK1), a kinase that is required for the activation of mitogen-
activated protein kinases (MAPKs) and NF-κB signaling (Abbott et al., 2007; Hasegawa 
et al., 2008; Yang et al., 2007). Together, these pathways trigger a potent antimicrobial 
and inflammatory host response. 
The role of NOD2 in maintaining inflammatory homeostasis is underscored by 




an inflammatory disease of the gastrointestinal tract (Hugot et al., 2001; Ogura et al., 
2001a). Conversely, gain-of-function mutations in NOD2 are associated with Blau 
syndrome and early onset sarcoidosis, two relatively rare disorders characterized by 
inflammation of the eyes, skin, and joints (Kanazawa et al., 2005; Miceli-Richard et al., 
2001). Genetic variation in the gene encoding NOD2 is, of all of the loci identified, the 
strongest known genetic risk factor in the development of CD. Because more than 70 loci 
have been identified that predispose to CD (Franke et al., 2010), it is possible that some 
of the genes associated with CD are involved in the regulation of the NOD2 signaling 
pathway. Thus, increased understanding of the NOD2 signaling pathway may provide 
insight into the pathogenesis of CD. 
Genome-wide, small interfering RNA (siRNA) screens are effective tools for 
identifying previously uncharacterized modulators of biological processes. Using a 
human cell line expressing human NOD2 and an NF-κB–responsive luciferase reporter, 
we performed a genome-wide siRNA screen aimed at identifying regulators of the NOD2 
signaling pathway. Our screen revealed many regulators of the NOD2 and NF-κB 
signaling pathways, including previously uncharacterized networks of positive and 
negative regulators. Additionally, we linked several genes associated with CD risk to the 
NOD2 signaling pathway. Together, our results provide a framework for understanding 
how gene networks contribute to the regulation of NOD2-mediated inflammatory 







MATERIALS AND METHODS 
 
Primary siRNA screen 
 
Human embryonic kidney (HEK) 293 cells stably expressing human NOD2 
(HEK293-NOD2) and an NF-κB luciferase reporter were cultured on 384-well plates 
(Greiner Bio-One) in Dulbecco's modified eagle medium with 10% fetal bovine serum, 2 
mM glutamine, 1 mM sodium pyruvate, and 1X Pen Strep (Gibco). Pools of four distinct 
siGENOME siRNAs (Thermo Scientific) were reverse transfected at a concentration of 
20 nM with Lipofectamine 2000 (Invitrogen) diluted in Opti-MEM (Invitrogen) for 48 
hours followed by stimulation with MDP (20 ng/ml, Bachem) for 18 hours. A 
PHERAstar plate reader (BMG Labs) was used to quantify both the cell viability assays 
(Cell Titre Fluor, Promega) and the NF-κB luciferase assays (Steady Glo, Promega), 
according to the manufacturer’s directions. 
 
Secondary validation assays 
 
Reporter cells were reverse transfected with 40 nM ON-TARGETplus siRNA 
pools (Thermo Scientific) for 48 hours, followed by stimulation with either MDP (20 








E. faecalis (ATCC 47077) or S. aureus (strain 8325-4, a gift from Timothy Foster, 
Trinity College, Dublin, Ireland) were inoculated into Brain Heart Infusion media and 
incubated overnight at 37C (for E. faecalis) or 30C (for S. aureus) with shaking. 
Overnight cultures were sub-cultured into fresh media and incubated at 37C with 
shaking for approximately 2 hours until reaching an OD600 of 0.6. The bacteria were 
washed and diluted in sterile phosphate-buffered saline (PBS). 40,000 bacteria were 
added to each well giving a bacterium to HEK293-NOD2 cell ratio of approximately 1:1. 
After a 1 hour infection, gentamicin (50 ng/μl, Gibco) was added to the media. 
Supernatants were collected after 17 hours. Luciferase and viability assays were carried 




HEK 293 cells were reverse transfected with 20 nM siRNA (siGENOME) as 
described earlier. After 48 hours, cells were transfected with pcDNA3, pcDNA3-
NOD2ΔLRR, pcDNA3-RIPK2ΔCT-FPK3, or pcDNA3-RIPK1ΔCT-FPK3 together with 
NF-κB luciferase and Renilla luciferase reporter plasmids. After 6 hours, some wells 
received 100 nM AP1510 (ARIAD) to induce dimerization. Eighteen hours later, cells 
were lysed in passive lysis buffer (Promega) and analyzed with the Dual Luciferase 
Reporter Assay System (Promega) according to the manufacturer’s instructions. 
 





Cell viability was analyzed with the CellTitre Fluor reagent (Promega) and read 
with a PHERAstar plate reader (BMG Labs) at the University of Michigan Center for 
Chemical Genomics. All cell viability values were calculated relative to multiple control 
wells of cells that received either non-targeting (NT) siRNA or Passive Lysis Buffer 
(PLB, Promega); such controls were present on each assay plate. The average value of 
the wells receiving NT siRNA was considered as 100%, and the average value of wells 
receiving PLB was considered as 0%. Therefore, wells with increased cell number had 
values greater than 100%, whereas those with decreased cell numbers relative to those of 
controls treated with NT siRNA had values less than 100%. 
 
NF-κB luciferase assay 
 
Activation of the NF-κB luciferase reporter was quantified with the Steady Glo 
reagent (Promega) and a PHERAstar plate reader in the University of Michigan Center 
for Chemical Genomics. The average relative luminescence values for each well were 
calculated relative to those of multiple control wells present on each plate. RIPK2-
specific siRNA was used as a positive control for plates in which cells were stimulated 
with MDP, whereas NT siRNA was used as a negative control. For each plate, the 
average value of wells receiving RIPK2-specific siRNA was considered as 100% 
inhibition, and the average value of wells receiving NT siRNA was considered as 0%. 
Therefore, test siRNA that resulted in decreased luciferase (relative to that of wells 




in increased luciferase (relative to that of wells receiving NT siRNA) resulted in values 
less than 0. For assay plates of cells stimulated with TNF-α, RelA-specific siRNA was 
used as the positive control. 
 
Measurement of IL-8 by ELISA 
 
Secretion of IL-8 into culture media was analyzed by Joel Whitfield in the 
University of Michigan immunology core facility. For assay plates in which cells were 
stimulated with MDP, normalized amounts of IL-8 were calculated relative to those of 
cells that received RIPK2-specific siRNA as well as those that received NT siRNA. For 
each plate, the average amount of IL-8 (in pg/ml) of wells receiving RIPK2-specific 
siRNA was considered as 100% inhibition, whereas the average amount of IL-8 in wells 
that received NT siRNA was considered as 0% inhibition. Therefore, test siRNA that 
resulted in decreased IL-8 secretion (relative to that of cells that received NT siRNA) 
resulted in values greater than 0, whereas test siRNA that resulted in increased IL-8 
secretion (relative to that of cells treated with NT siRNA) resulted in values less than 0. 
For assay plates stimulated with TNF-α, the average value of IL-8 secreted by cells that 
received RelA-specific siRNA was considered as 100% inhibition. 
 




/J mice (ncf1 mutant mice) were obtained from the Jackson 




conducted under protocols approved by the University of Michigan Committee on Use 
and Care of Animals. BMDMs were isolated as previously described (Celada et al., 
1984). Briefly, femurs and tibia were removed from euthanized mice after sterilization 
with 70% ethanol. Bone marrow cells were resuspended in L-cell-conditioned complete 
Iscove's Modified Dulbecco's media (Gibco) and cultured for 5 to 6 days before overnight 
stimulation with MDP (10 μg/m) and subsequent analysis of IκB and MAPK proteins by 
Western blotting (Cell Signaling Technology Inc.). 
 
Bioinformatics and statistical analysis 
 
A custom-built relational database (M-screen) was developed and used for data 
storage, display, analysis, and queries (available at: 
http://mscreen.lsi.umich.edu/index.php). Assay quality was determined by calculating 
mean, standard deviation, coefficient of variation, and Z′ factor (Zhang et al., 1999) 
values for each plate. After initial normalization to positive and negative controls on each 
plate, an additional normalization step was performed to normalize the percentage 
knockdown luciferase values to those for viability. Because the normalized knockdown 
luciferase values ranged from negative values to >100%, to convert to the luciferase 
scale, we first subtracted the values from their maximum rather than from 100. After 
normalization with the percentage viability, we then converted back to the percentage 
knockdown scale.  
The specific formula used was: max (L) – (100(max (L) - L) / V), where L = the 




Values were then normalized to the median of each plate, because substantial shifts in 
plate-to-plate medians were observed, and then global median normalization was used as 
a final step to make the samples comparable. To calculate P values, we tested for 
normalized knockdown luciferase values that were statistically significantly higher or 
lower than the overall median. We used an empirical Bayes method (a moderated t-test) 
that takes into account the relationship between the percentage knockdown of luciferase 
activity and variance to calculate P values (Sartor et al., 2006), enabling more accurate 
sample variation estimates for each gene. P values were adjusted for multiple testing with 
the Bonferroni correction. Secondary validation analyses were performed in triplicate on 
313 hits from the primary screen spread over two separate assay plates. For each of these 
plates, we analyzed both luciferase and IL-8 data by following the same steps as 




Genome-wide siRNA screen identifies regulators of NOD2 signaling 
 
To identify regulators of the NOD2 signaling pathway, we performed a genome-
wide siRNA screen. We engineered a luciferase-based reporter cell line derived from 
highly transfectable HEK 293 cells, and used this line to quantitatively measure NOD2-
dependent signaling (Figure 2.1A). HEK 293 cells are a well-established model for 
interrogating NOD2 signaling because they do not naturally have detectable amounts of 




2003). However, stimulation of HEK 293 cells stably expressing NOD2 with MDP 
resulted in NF-κB activation, phosphorylation of p38 MAPK, and secretion of the pro-
inflammatory chemokine interleukin-8 (IL-8) (Figure 2.2). We developed a 
bioluminescence assay to monitor NF-κB activation with a stably incorporated luciferase 
reporter gene downstream of tandem copies of a consensus NF-κB–binding site. The 
screen was performed in triplicate with a commercially available siRNA library targeting 
18,110 genes (Figure 2.1B). The extent of luciferase activity after stimulation of cells 
with MDP was measured and displayed relative to that of cells transfected with control 
siRNAs present on each plate. On average, across all of the assay plates used in the 
screen, cells transfected with non-targeting (NT) siRNA and stimulated with MDP 
resulted in ~50-fold induction in luciferase activity. In comparison, the extent of 
luciferase induction upon silencing RIPK2, a serine and threonine protein kinase required 
for NOD2-dependent NF-κB activation (Kobayashi et al., 2002) was on average ~7 fold, 
representing an 86% reduction in the extent of NOD2 signaling. 
To enable comparisons to be made between plates, we normalized both luciferase 
and viability data sets with multiple positive and negative control wells present on each 
assay plate (Figure 2.3). For both the luciferase and viability assays, the data gave a 
normal distribution (Figure 2.4). Most of the Z’ factor scores, a measure of assay quality 
(Zhang et al., 1999), for each assay plate were above 0.5 for both the luciferase and 
viability data sets, indicating a signal-to-noise ratio sufficient for performing robust high-
throughput screens (Figure 2.5). 
We classified genes as NOD2 regulators if their silencing reproducibly decreased 




activity (negative regulators) relative to that of controls treated with NT siRNA (Figure 
2.1C and Figure 2.4). To avoid nonspecific effects of gene silencing on cell number, we 
used a fluorescence-based viability assay (Niles et al., 2007). Control wells present on 
each assay plate were used to calculate the percentage of viable cells (Figure 2.1D). The 
luciferase signal weakly correlated with cell viability, especially for genes whose 
knockdown resulted in reduced viability, which most likely reflected a lack of sufficient 
cell numbers to produce luciferase (Figure 2.6). Therefore, we considered those genes 
whose silencing resulted in either (i) enhanced luciferase signal and increased viability 
(>120%) or (ii) decreased luciferase signal and decreased cell viability (<70%) to be 
inconclusive with respect to their effect on NOD2 signaling because of their nonspecific 
effects on cell viability. For example, knockdown of genes involved in core house-
keeping functions, such as transcription and translation (Figure 2.7A) and cell survival 
(Figure 2.7B), resulted in decreases in both cell viability and luciferase activity. 
Together, these results demonstrate the importance of using a cell viability control to 
avoid false positives and to provide increased confidence in the ability of our screen to 
properly identify genes involved in the regulation of the NOD2–NF-κB signaling 
pathway. 
 
Numerous NOD2 regulators interact with core components of the NF-κB pathway 
 
To confirm the validity of our experimental approach, we examined how known 
components of the NOD2 signaling pathway behaved in the screen. Indeed, knockdown 




NF-κB1, and avian reticuloendotheliosis viral oncogene homolog A (RelA) substantially 
diminished NOD2-dependent luciferase activity (Figure 2.1E), thereby validating our 
approach. In addition, two serine and threonine kinases involved in NF-κB activation, 
protein kinase C δ (PRKCD) (Lallena et al., 1999) and casein kinase 2 alpha’ 
(CSNK2A2) (Bird et al., 1997), were both classified as positive regulators in the screen 
(Figure 2.1E). Notably, Klotho (KL), an anti-inflammatory protein that suppresses NF-
κB signaling (Zhao et al., 2011), and PDZ and LIM domain protein 2 (PDLIM2), a RelA-
binding protein that inhibits NF-κB signaling through its E3 ubiquitin ligase activity 
against RelA (Tanaka et al., 2007), were each classified as negative regulators in the 
screen (Figure 2.1E).  
Consistently, many proteins known to interact with core components of the NOD2 
and NF-κB signaling pathways were categorized as positive and negative regulators in 
the screen (Figure 2.8). For example, the NOD2-interacting protein carbamoyl phosphate 
synthetase/aspartate transcarbamylase/dihydroorotase (CAD) was revealed as a negative 
regulator in the screen, consistent with previous reports (Gewurz et al., 2012; Richmond 
et al., 2012). Furthermore, PPP2R5E (protein phosphatase 2, regulatory subunit B', 
epsilon isoform), another NOD2-interacting protein (Nimmo et al., 2011), was 
categorized as a positive regulator of NOD2 signaling. Similarly, numerous RIPK2-, 
NEMO-, and RelA-interacting proteins were identified as either positive or negative 
regulators (Figure 2.8A and B). Furthermore, enrichment analysis of the top 700 positive 
regulators from the screen revealed components of the proteasome (Figure 2.8C) and 
nuclear pore complex (Figure 2.8D) were present more often than what would be 




inhibitor of κB (IκB) degradation and translocation of NF-κB to the nucleus. Overall, the 
ability of our screen to identify many proteins already implicated in the regulation of the 
NOD2 and NF-κB signaling pathways validated our screening approach and provided 
increased confidence in our discovery of the many putative regulators not previously 
connected with NOD2 signaling. 
 
Analysis of intersecting data sets reveals networks of putative NOD2 regulators 
 
Next, we used additional lines of biochemical and functional data from the 
literature to identify experimental evidence supporting connections among hits from the 
screen. In one approach, we used the Search Tool for the Retrieval of Interacting Genes 
(STRING) database (Szklarczyk et al., 2011) to reveal numerous protein-protein 
interactions (PPIs) among hits from the screen (Figure 2.9). For example, PPIs between 
two members of the endosomal sorting complex required for transport (ESCRT)-1 
complex, tumor susceptibility gene 101 (TSG101) and vacuolar protein sorting 28 
(VPS28), and three proteins involved in autophagy, ATG4A, ATG4B, and -
aminobutyric acid receptor-associated protein (GABARAP), were identified among 
putative NOD2 negative regulators. In addition, multiple components of the nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase complex, including neutrophil 
cytosolic factor (NCF1), cytochrome b-245 beta (CYBB), and NADPH oxidase activator 
1 (NOXA1), were each classified as positive regulators in the screen. Together, these 




number of putative regulators and offer potential mechanistic insight into the level at 
which these regulators may act to regulate NOD2 signaling. 
Given the link between NOD2 and CD, we compared genes categorized as hits in 
our screen with those associated with CD risk by genome-wide association studies 
(GWAS). Fifteen genes associated with CD risk were identified as hits in our screen 
(Figure 2.10). In addition, multiple genes whose products interact with these CD risk 
factors were also categorized as hits in our screen. These results not only support a role 
for these gene products in NOD2 signaling, but they also suggest that these regulators of 
the NOD2 and NF-κB signaling pathways may play a role in the pathogenesis of CD. 
 
Multiple NOD2 regulators were confirmed in secondary validation assays 
 
To verify that the hits identified in our primary screen were bona fide regulators 
of NOD2 signaling, we carried out a series of secondary validation experiments with 
alternative siRNA pools that targeted 313 genes from our primary screen (Figure 2.11). 
In addition to measuring the induction of NF-κB–dependent luciferase activity, we used 
enzyme-linked immunosorbent assay (ELISA) analysis to measure IL-8 secretion, whose 
production is partially dependent on NF-κB activation (Yasumoto et al., 1992). We found 
that 25% of the putative positive regulators and 33% of the putative negative regulators 
tested were concordant between the primary and secondary screens, a confirmation rate 
similar to those reported for other genome-wide siRNA screens (Figure 2.11B) (Chiang 




For example, siRNA-mediated knockdown of NCF1, a critical component of the 
NADPH complex that regulates the generation of reactive oxygen species, diminished 
NOD2-dependent NF-κB activity in both the primary and secondary screens (Figure 
2.12A and B). Given that many molecules that interact with NCF1 were identified as 
positive regulators in the primary screen (Figure 2.9A), we continued to validate these 
results with primary bone marrow–derived macrophages (BMDMs) from Ncf1-deficient 
(Ncf1
–/–
) mice stimulated with MDP and analyzed for activation of the NOD2 pathway by 
Western blotting. BMDMs from Ncf1
–/–
 mice exhibited impaired degradation of IκB 
compared to those from wild-type control mice (Figure 2.12C); however, p38 MAPK 
activation was not affected (Figure 2.12D). Moreover, the accumulation of 
phosphorylated IκB (pIκB) in Ncf1-deficient cells (Figure 2.12C) further supports an 
inability to properly degrade IκB, which is consistent with a role for NCF1 in mediating 
MDP-induced NF-κB activation. 
 
Stimulation of cells with TNF-α identifies general regulators of NF-κB signaling 
 
Because NOD2 signals through NF-κB, we were interested in separating 
candidate regulators that specifically regulate NOD2 signaling from those that are more 
general regulators of NF-κB signaling. To distinguish between these two possibilities, we 
measured NF-κB activation in response to stimulation with either MDP or TNF-α. As 
predicted, knockdown of RIPK2 inhibited MDP-induced, but not TNF-–induced, NF-
κB–dependent luciferase activity, whereas knockdown of RIPK1 inhibited TNF-α–




Comparison of the responses to MDP and TNFα for each gene revealed that most of the 
tested genes affected both MDP- and TNF-α–induced NF-κB signaling, suggesting that 
most of the validated hits are likely downstream of RIPK2 and act as general regulators 
of the NF-κB pathway. 
Apart from RIPK1 and RIPK2, we did not observe genes exhibiting robust 
specificity for either MDP or TNF-α. However, knockdown of ring finger protein 31 
(RNF31) and zinc finger, DHHC-type containing 2 (ZDHHC2) exhibited more 
substantial inhibition of MDP-induced luciferase activity than of TNF-α–induced 
luciferase activity (Figure 2.11C). To explore the level at which ZDHHC2 and RNF31 
regulated NOD2 signaling, we performed epistasis analysis with various constructs that 
stimulate NF-κB signaling from different points in the pathway (Fig 2.11D and Figure 
2.13). We used a constitutively active (CA) version of NOD2 that lacks the inhibitory C-
terminal leucine-rich repeats, as well as the inducibly active (IA) fusion proteins RIPK2-
ΔCARD-Fpk3 (RIPK2 IA) and RIPK1-ΔCARD-Fpk3 (RIPK1 IA) whose CARD 
domains are replaced by tandem FK506 binding protein (FΚBP)-related dimerization 
domains. Previous studies showed that enforced oligomerization of RIPK2 or RIPK1 
induces NF-κB activation that is dependent on the FΚBP-specific dimerization agent 
AP1510 (Inohara et al., 2000). Using this approach, we showed that siRNA-mediated 
knockdown of RIPK2 inhibited activation of NF-κB signaling when stimulated with CA 
NOD2 or IA RIPK2, but not with IA RIPK1 alone, consistent with a specific requirement 
for RIPK2 in NOD2 signaling (Fig. 5D). However, knockdown of RNF31 (Figure 




constructs, indicating that both RNF31 and ZDHHC2 are capable of affecting NF-κB 
signaling downstream of RIPK1 and RIPK2. 
 
Members of LUBAC positively mediate NOD2 signaling 
 
The ubiquitin conjugation machinery plays a critical role in the regulation of NF-
κB signaling (as reviewed by Liu and Chen, 2011). Linear ubiquitination mediated by the 
linear ubiquitin chain assembly complex (LUBAC) plays a role in the regulation of 
canonical NF-κB signaling in response to various stimuli, such as TNF-α, interleukin-1β 
(IL-1β), and lipopolysaccharide (LPS) (reviewed by Emmerich et al., 2011). LUBAC is 
composed of three components: RanBP-type and C3HC4-type zinc finger containing 1 
(RBCK1), SHANK-associated RH domain–interacting protein (SHARPIN), and RNF31, 
the latter two of which were identified as positive regulators of NF-κB in our screen. 
Analysis of protein-protein interaction databases identified a network of LUBAC-
interacting proteins among hits from our primary screen linking LUBAC to core 
components of the NF-κB signaling pathway (Figure 2.14A and B). For example, two of 
the proteins in this network, RNF31 and ubiquitin-conjugating enzyme E2 D3 
(UBE2D3), are known to be involved in the degradation of IκB (Gonen et al., 1999) and 
the ubiquitination of NEMO (Tang et al., 2003), and both were validated in our 
secondary assays (Figure 2.14C). Knockdown of RNF31 resulted in diminished MDP-
induced NF-κB luciferase activity and IL-8 secretion but had only a weak effect on TNF-




regulator of MDP-induced NF-κB luciferase activity, but had no effect on MDP-induced 
IL-8 secretion or TNF-α–induced signaling. 
To further examine roles for RNF31 and UBE2D3 in stimulating NF-κB 
activation, we treated our reporter cells with two different Gram positive bacteria that 
activate NOD2 signaling. We chose the common intestinal commensal bacterium 
Enterococcus faecalis, given the required role of NOD2 in mediating a cytokine response 
(Kim et al., 2011), and Staphylococcus aureus, another commensal organism that triggers 
a NOD2-mediated cytokine response both in vitro (Hruz et al., 2009) and in vivo 
(Deshmukh et al., 2009). We found that RNF31 was a positive regulator of bacterially-
induced NF-κB luciferase activity and IL-8 secretion in response to S. aureus, whereas 
UBE2D3 positively regulated S. aureus-induced NF-κB luciferase activity and IL-8 
secretion, as well as E. faecalis-induced NF-κB luciferase activity, but not IL-8 secretion 
(Figure 2.14D). Together, these results support a critical role for LUBAC as a general 
regulator of NF-κB signaling and specifically in the modulation of NF-κB signaling 




Coordination of the inflammatory response is mediated by a wide range of 
effectors, and proper balance of responses is required for the maintenance of health 
(Medzhitov, 2008). NOD2 signaling is capable of activating the NF-κB pathway, leading 
to an inflammatory response to bacteria that is dysregulated in human diseases such as 




reside within the cytoplasm where they are kept inactive because of physical associations 
with IκB family members. Degradation of IκB by the proteasome exposes a nuclear 
localization signal in NF-κB, which mediates its relocalization to the nucleus where it can 
bind to DNA and regulate the transcription of various target genes. Multiple core 
components of NOD2 and NF-κB signaling pathways including RIPK2, NEMO, NF-
κB1, RelA, and subunits of the proteasome and the nuclear pore complex were classified 
as hits in our screen, providing evidence that our screen accurately detected bona fide 
NOD2 regulators. In addition, our genome-wide siRNA screen expanded the number of 
genes implicated in the regulation of the NOD2 and NF-κB signaling pathways. 
Many steps in the NF-κB signaling pathway are regulated by protein 
ubiquitination (Liu and Chen, 2011). For example, Lys
63
-linked poly-ubiquitination of 
NEMO, an IKK scaffolding and regulatory protein, mediates the recruitment of the IKK-
activating kinase TAK1. Consistent with this, our screen identified protein phosphatase 
magnesium-dependent 1 like (PPM1L), a phosphatase that binds to and dephosphorylates 
TAK1 (Li et al., 2003), as an inhibitor of NOD2 signaling analogous to its previously 
reported role as an inhibitor of NF-κB activation downstream of TNF-α (Li et al., 2006). 
Furthermore, we observed decreased NOD2 signaling upon knockdown of two 
components of LUBAC (RNF31 and SHARPIN), which is consistent with reports 
showing a role for LUBAC in the regulation of NOD2 signaling (Damgaard et al., 2012). 
Our results extend these observations by showing a role for RNF31 in the activation of 
the NOD2 pathway in response to bacterial stimulation. In vivo, sharpin deficient mice 
exhibit excessive inflammation (Seymour et al., 2007), impaired secretion of pro-




Tokunaga et al., 2009; Wang et al., 2012), features that are somewhat analogous to the 
symptoms of CD. Biochemically, SHARPIN interacts with RNF31, and together they 
play a role in NF-κB activation by acting as an E3 ubiquitin ligase to catalyze the linear 
ubiquitination of NEMO (Gerlach et al., 2011; Ikeda et al., 2011; Niu et al., 2011; 
Rahighi et al., 2009), which agrees with our secondary validation data showing a positive 
role for RNF31 in TNF-α–induced NF-κB activation.  
Although RBCK1, the third known component of the LUBAC complex, was not 
individually identified as a hit in our screen, Parkinson protein 2 (PARK2), a protein with 
the same domain structure as RBCK1 and that was previously implicated in NF-κB 
signaling (Henn et al., 2007), was classified as a positive regulator of NOD2 signaling. 
Notably, PARK2, like NOD2 and RIPK2, is linked to susceptibility to leprosy (Mira et 
al., 2004; Zhang et al., 2009). Furthermore, UBE2D3, an E2 ubiquitin conjugation 
enzyme that interacts with RBCK1 (Zenke-Kawasaki et al., 2007) was validated as a 
stimulator of NOD2 signaling in our screen. In addition, two ubiquitin-specific proteases 
(USP), USP2 and USP36, previously associated with TNF-α–induced NF-κB signaling 
(Metzig et al., 2011), were classified as positive regulators of NOD2 signaling. Together, 
these data show a role for protein ubiquitination and, in particular, LUBAC, in NOD2 
signaling. 
Since protein-protein interactions mediate the assembly and regulation of signal 
transduction pathways, we were pleased to identify numerous proteins known to interact 
with NOD2 and other core components of the NF-κB signaling pathway as hits in our 
screen. In addition, our screen implicated several additional protein complexes in the 




role in the inhibition of NOD2 signaling is supported by the enhanced IL-8 secretion in 
response to NOD1 signaling that was observed upon knockdown of ESCRT-I complex 
subunit tumor susceptibility gene 101  (TSG101) (Yeretssian et al., 2011). In addition, 
several genes associated with CD appear to regulate oxidative stress (Khor et al., 2011), 
consistent with our identification of several components of the NADPH oxidase complex 
as regulators of NOD2 signaling. Finally, multiple interacting components of autophagy, 
an evolutionarily conserved process required for the degradation and recycling of cellular 
contents that can limit infection by certain intracellular pathogens, were identified as 
inhibitors of NOD2 signaling in our screen, the relevance of which is increased given 
evidence of their biochemical links to NOD2 (Homer et al., 2010; Travassos et al., 2010) 
coupled with the observation that multiple components of the autophagy network are 
associated with an increased risk of CD (reviewed by Fritz et al., 2011). Together, these 
examples illustrate the use of overlaying siRNA screening data with protein-protein 
interaction networks to provide insight into the regulatory mechanisms by which these 
proteins may influence NOD2 signaling, and to generate models worth pursuing by more 
traditional hypothesis-based research. 
The NOD2 signaling pathway is just one of many upstream inputs that converge 
on the IKK complex and regulate the evolutionarily conserved NF-κB stress response 
pathway. These branches are unlikely to function in isolation in vivo. Therefore, we 
suggest that the relatively large number of genes identified to influence NOD2 signaling 
by our screen likely includes direct regulators as well as gene products in parallel 
pathways that indirectly affect NF-κB signaling. Indeed, our TNF-α counter screen 




κB signaling. This lack of NOD2-specific components supports the idea that different 
danger-sensing receptors of the innate immune system likely use a small number of 
specific components before converging on a more general core NF-κB response. 
Biologically, activation of the NOD2 and NF-κB signaling pathways is critical for 
host defense against pathogens (reviewed by Franchi et al., 2009). Tight control of both 
the strength and duration of this response is necessary to achieve a balance between 
uncontrolled infection and tissue damage associated with chronic inflammation (Ruland, 
2011). Our screen identified many inhibitors of the NF-κB pathway. For example, MDP-
induced activation of NF-κB was enhanced upon silencing PDLIM2, a protein that 
interacts with RelA and mediates its degradation (Tanaka et al., 2007). Furthermore, we 
validated the RNA-binding protein FUS and its interacting partner FUSIP1 as inhibitors 
of NOD2 signaling in our siRNA screen. The systematic identification of genes whose 
products inhibit NF-κB signaling will improve our understanding of how this critical 
pathway is restricted and may provide new avenues for therapeutic intervention. 
In conclusion, we have identified numerous genes that regulate the NOD2 and 
NF-κB signaling pathways, providing a resource for future hypothesis-based studies 
aimed at understanding the detailed molecular mechanisms that regulate these pathways. 
It is becoming increasingly clear that complex networks of interacting proteins, and not 
simple linear pathways, are involved in the regulation of innate immunity. Our study 
offers a systems-level glimpse of the NOD2 signaling pathway, which will increase our 
understanding of how this pathway regulates inflammatory homeostasis and provides 
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Figure 2.1 │ A genome-wide siRNA screen identifies regulators of NOD2 signaling 
(A) Schematic representation of the reporter cell line engineered to quantitatively assess MDP-
induced NOD2 signaling together with known components of the NOD2 signaling pathway. (B) 
The screen was carried out in triplicate with pools of four distinct siRNAs specific for each gene. 
Pie charts summarize the percentages of genes whose silencing affected cell viability and the 
percentages of genes not affecting viability that either decreased (red) or increased (blue) 
luminescence. (C) Rank-order plot of the average normalized NF-B luciferase reporter activity 
displayed relative to positive (RIPK2) and negative (nontargeting, NT) siRNA controls present on 
each assay plate. (D) Rank-order plot of the average percentage cell viability displayed relative 
to NT siRNA and lysed cell controls present on each assay plate. (E) siRNA-mediated silencing of 
known components of the NOD2 signaling pathway led to decreased (red) or increased (blue) 
NF-B luciferase activity relative to that of NT control siRNA cells (upper panel) without major 
effects on cell viability (lower panel). All luminescence values were statistically significant with P 












































































































































Infection Expands Extramedullary Hematopoietic Stem Cells Through NOD-like-




 Adult hematopoietic stem cells (HSCs) are maintained primarily in specialized 
niches within the bone marrow and may engage in extramedullary hematopoiesis during 
periods of stress, yet the underlying mechanisms are largely unknown.  We show that 
infection with the gram negative bacterium Escherichia coli resulted in marginal 
reduction of bone marrow HSCs, but induced robust expansion of functional HSCs in 













 fractions while subsets of HSCs had increased expression of CD48 and Lineage 
markers during infection.  Expansion of splenic HSCs was diminished in TLR4 deficient 
and RIPK2 deficient mice, implicating TLRs and NOD1/NOD2 signaling in the 
activation of HSCs after infection.  Dual stimulation of NOD1 and TLR4 expanded HSCs 
and progenitors in spleen, which was dependent on G-CSF and correlated with reduced 
CXCL12 in bone marrow.  Expression of TLR4 and RIPK2 in radio-resistant cells was 
required, while TLR4 expression on HSCs was dispensable. Our studies highlight a role 
for NLR and TLR signaling in radio-resistant cells to induce the production of 




results indicate that bacterial infection has minimal effect on bone marrow HSCs, but 




Hematopoietic stem cells are defined by their ability to give rise to all cells of the 
blood system and to self-renew, where cell division results in at least one daughter that 
retains the full developmental potential of its parent.  The majority of HSCs reside in the 
bone marrow where they are surrounded by a network of supporting cells, collectively 
termed the stem cell niche. A smaller subset of HSCs reside in the spleen, which serves 
as a site for hematopoiesis during embryogenesis and periods of duress (Morrison and 
Spradling, 2008).  While residency in a niche is essential for HSC maintenance, HSCs 
regularly traffic through the blood stream in a process that may facilitate competition for 
niches to ensure a robust pool of stem cells (Wright et al., 2001).  Moreover, HSCs have 
been isolated from lymphatic ducts, indicating that HSCs travel through peripheral tissues 
and have the potential to provide a local source of cell production (Massberg et al., 2007).    
While much is known about HSC activity under homeostatic conditions, how HSCs 
function during stress is less well understood.   
Bacterial infection is a common form of stress that can induce profound effects on 
the fate of hematopoietic stem and progenitor cells (HSPCs).  Host-derived pattern 
recognition receptors (PRRs) sense components of bacteria and respond by activating 
pro-inflammatory signaling pathways that aid in the defense against infection.  




sensed by Toll-like receptor 4 (TLR4), and peptidoglycan, whose cleavage products are 
sensed by the nucleotide-binding oligomerization domain containing (NOD)-like-
receptors (NLRs) NOD1 and NOD2.  TLR4 signals via the adaptor proteins myeloid 
differentiation primary response 88 (Myd88) and TIR-domain-containing adapter 
inducing interferons (TRIF), while NOD1 and NOD2 signaling requires the adaptor 
protein receptor-interacting serine-threonine kinase 2 (RIPK2), which leads to the 
activation of NF-κB and MAPK pathways (Franchi et al., 2009; Sartor, 2008).   







cells, which mark both HSCs and non-self-renewing progenitors, suggesting that HSPCs 
may actively participate in innate immune responses (Nagai et al., 2006).  Activation of 
TLRs has been proposed to alter the fate and function of HSCs either directly, or 
indirectly via production of inflammatory cytokines or alterations in the bone marrow 
niche (Baldridge et al., 2010; Chen et al., 2010; Esplin et al., 2011; Essers et al., 2009; 
Johns et al., 2009; Rodriguez et al., 2009; Scumpia et al., 2010; Takizawa et al., 2011).  
Only one study tested the function of HSCs following live bacterial infection (Baldridge 
et al., 2010), but they did not assess HSC activity in unfractionated bone marrow or in 
sites of extramedullary hematopoiesis such as the spleen.  Moreover, no study has 
characterized the surface marker profile of functional HSCs after infection.  Thus, it is 
unclear whether bacterial infection alters the phenotype and function of HSCs in the bone 
marrow and spleen.  Furthermore, it remains to be determined whether HSCs directly 
sense and respond to components of bacteria or whether infection merely alters the bone 




Activation of TLRs can also affect the localization of HSPCs.  Systemic 
administration of LPS results in the accumulation of HSPCs in the spleen (Esplin et al., 
2011; Vos et al., 1972), but the signals and cell types responsible for driving this 
phenomenon are unknown.  Repeated administration of granulocyte-colony stimulating 
factor (G-CSF), which can be produced in response to infection or LPS (Hareng and 
Hartung, 2002), induces the mobilization of HSPCs from bone marrow to peripheral 
blood and spleen and is the preferred mobilizing agent used in the clinic (Duhrsen et al., 
1988; Molineux et al., 1990; Morrison et al., 1997; To et al., 2011).  While the 
mechanisms of G-CSF induced mobilization are well characterized (Levesque and 
Winkler, 2008; Mazo et al., 2011), it is currently unclear whether the production of 
endogenous G-CSF contributes to alterations in HSC activity during infection.  Here we 
investigated mechanisms underlying how bacteria influence the localization and function 
of HSCs. 
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 mice were kindly provided by Grace 
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SPF conditions at the University of Michigan.  All experiments were approved by the 




KF1B and E. coli K12 were graciously provided by Naohiro Inohara (University of 
Michigan, USA).  Ultrapure LPS (E. coli K12) was purchased from Invivogen.  For 
experiments using bacterial compounds, 50 ug of KF1B and/or 100 ug of LPS was 
diluted in PBS and injected i.p. Anti-mouse G-CSF blocking antibody (clone 67604, 
R&D Systems, Minneapolis, MN, USA) and rat IgG1 isotype control were provided by 
Ian Wicks (WEHI, Australia) as a gift from CSL Limited, Australia, and used as 
described previously (Lawlor et al., 2004).  For these experiments, 250 ug of antibody 
was diluted in PBS and injected i.p. one hour prior to injection of bacterial compounds. 
 
Cell isolation and flow cytometry 
 
Bone marrow cells were isolated by flushing one femur and tibia with 3 mL Ca2+ 
and Mg2+ free HBSS supplemented with 2% HI FBS and filtering through a 50 μm mesh 
and counted using a hemocytometer.  Splenocytes were obtained by mashing the organ 
between two glass slides and filtering through a 100 μm mesh.  Populations were 
visualized using combinations of antibodies listed in Table 3.1. 
 





Ten week or older recipient mice were lethally irradiated using X-ray (Phillips 
RT250, Kimtron Medical) with two doses of 540 rad (total 1080) delivered between 3 
and 24 hours apart.  In some experiments, 3x10
5
 WBM or 1x10
6
 splenocytes were mixed 
with 3x10
5
 competitor whole bone marrow and transplanted via tail vein injection.  To 
determine the surface marker profile of HSCs, total bone marrow or spleen was harvested 
from mice six days after infection, purity sorted to enrich for the positive or negative 
fraction, purity sorted again and mixed with 3x10
5
 WBM prior to retro-orbital injection.  
Recipient mice were maintained on antibiotic water (neomycin sulphate 1.11g/L and 
polymyxin B sulfate 0.121 g/L, 50 g/L sucrose) for at least 6 weeks.  In experiments 
where live E. coli exposed tissues were transplanted, recipient mice received 5 mg/kg 
enrofloxacin (Bayer) i.v. at day 0 and s.c. at day 5 post transplant.  Recipient mice were 
bled every four weeks to determine reconstitution.    To generate reverse chimeras, 5x10
6
 









 mice and recipients were allowed to recover for 16 
weeks prior to challenge. 
 
Bacterial culture and infection 
 
 E. coli K12 was picked from frozen glycerol stock into LB broth, shaken at 37 
C overnight, and sub-cultured in LB for another 2 hrs.  Bacteria were washed multiple 




injected i.p. with 200 uL of bacteria diluted in PBS and residual bacteria was serially 




WBM was homogenized using a column (Omega) and RNA was isolated using a 
Total RNA kit (Omega).  Eluted RNA was reverse transcribed into cDNA using High-
Capacity RNA-to-cDNA kit (Applied Biosystems).  Quantitative real-time PCR was 
performed using SYBR Green (Applied Biosystems). Gene expression was normalized to 
the house keeping gene GAPDH.  Primers for CXCL12 were F- 
TGCATCAGTGACGGTAAACCA and R- GTTGTTCTTCAGCCGTGCAA.  Primers 
for GAPDH were F- TGCGACTTCAACAGCAACTC and R- 




Splenocytes were counted using a hemocytometer, diluted in Methocult M3434 
medium (Stem Cell Technologies) and incubated at 37 C for 8-12 days after which 




All statistics were performed using Graphpad Prism software.  Statistical tests 







Systemic E. coli infection reduces functional HSCs in bone marrow 
 
To understand the mechanisms underlying the regulation of HSCs during 
infection, we developed a model of systemic infection using the gram negative bacterium 
Escherichia coli K12.  This bacterium was chosen because systemic administration was 
sub-lethal in wild type (WT) mice for all conditions tested.  To determine whether HSC 
activity is altered in the bone marrow after E. coli infection, we performed competitive 
transplantation experiments in which WT (CD45.1) mice were treated with PBS or E. 
coli and after six days, 3x10
5
 whole bone marrow (WBM) were mixed with 3x10
5
 
untreated (CD45.2) WBM and transplanted into lethally irradiated (CD45.2) recipients 
and peripheral blood reconstitution was followed for 16 weeks (Figure 3.1A and B).  To 
quantitatively compare levels of reconstitution, we converted percent chimerism after 16 
weeks into repopulating units (RUs) (Harrison et al., 1993). In two independent 
experiments, WBM from E. coli infected mice had on average 2.1-fold fewer RUs 
compared with PBS treated WBM (Figure 3.1A).  The contribution of E. coli infected 
WBM to the B-lineage was significantly reduced, while contribution to myeloid and T-
lineages trended toward a reduction (Figure 3.1B).  These results indicate that total HSC 
activity in the bone marrow of mice infected with E. coli for six days was diminished 





Systemic E. coli infection expands functional HSCs in spleen 
 
The spleen can serve as a site for extramedullary hematopoiesis during periods of 
stress and previous studies have found that treatment of mice with LPS, which mimics 
some aspects of infection, expands HSPCs in the spleen (Esplin et al., 2011; Vos et al., 
1972).  To determine whether HSC activity is altered in the spleen after live bacterial 
infection, we treated WT (CD45.1) mice with PBS or E. coli and after six days mixed 
1x10
6
 splenocytes with 3x10
5
 untreated (CD45.2) WBM and transplanted these cells into 
lethally irradiated (CD45.2) recipients and followed peripheral blood reconstitution for 
16 weeks (Figure 3.1C and D). In two independent experiments, splenocytes from E. 
coli infected mice had on average 38.9-fold more RUs than splenocytes from PBS treated 
mice (Figure 3.1C). We defined long term multilineage reconstitution (LTMR) activity, 
characteristic of functional HSCs, as the presence of greater than 0.3% of donor-derived 
myeloid, T-lineage and B-lineage cells at 16 weeks post transplant. Whereas splenocytes 
from PBS treated donors contributed minimally to myeloid and lymphoid lineages over 
16 weeks (2/9 LTMR), consistent with a very small resident population of splenic HSC 
under steady-state conditions, splenocytes from E. coli infected donors contributed 
robustly to myeloid and lymphoid lineages over 16 weeks (9/9 LTMR) (Figure 3.1D).  
These results indicate that functional HSC activity is enhanced in the spleens of mice 
infected with E. coli for six days compared with spleens of uninfected mice. 
 



























 fraction of bone marrow under steady-state conditions (Kiel et al., 2005), yet 
administration of live bacteria, LPS or inflammatory cytokines can alter the expression of 
these surface markers on various cell types (Howie et al., 2002; Munitz et al., 2006; 
Zhang et al., 2008).  Therefore we set out to determine whether functional HSCs retain 
their surface marker profile during infection.  We performed competitive reconstitution 
experiments where bone marrow or spleen from E. coli infected mice was fractionated 
based on positive or negative expression of CD150 or CD48 (Figure 3.2).  We 
transplanted donor cells based on the percentage of each population within infected bone 
marrow or spleen.  The total number of cells transplanted for each condition is listed in 
Table 3.2.  In two independent experiments, all mice that received CD150
+
 bone marrow 
cells (10/10 LTMR) and spleen (7/7 LTMR) were long term multilineage reconstituted 
whereas all mice that received CD150
-
 bone marrow cells (0/9 LTMR) and spleen (0/9 
LTMR) exhibited transient myeloid reconstitution with sustained yet limited lymphoid 
reconstitution (Figure 3.2A and B; Table 3.3).  This is consistent with previously 
published data indicating that CD150
-
 bone marrow cells contain transiently 
reconstituting multipotent progenitors (Kiel et al., 2008). 
 
Under steady-state conditions, all LTMR activity in adult bone marrow is 
contained within the CD48 negative fraction of cells (Kiel et al., 2005).  In E. coli 
infected mice, while 7/10 and 9/10 recipients of CD48
-
 bone marrow and spleen, 
respectively, were LTMR, we found that 2/10 and 2/10 recipients of CD48
+
 bone marrow 




indicate that all HSC activity is present in the CD150
+
 fraction and a majority is present 
in the CD48
-
 fraction of bone marrow and spleen, while a minority of HSC activity is 
present in the CD48
+
 fraction of bone marrow and spleen six days after E. coli infection. 
We performed similar experiments by sorting bone marrow and spleen from 
infected mice based on positive or negative expression of Sca1, cKit or Lineage markers 





and a majority of HSC activity was present in the Lineage
-/low
 fraction of bone marrow 
and spleen during infection. A minority of HSC activity was present in the Lineage
+
 
fraction of the bone marrow but not the spleen (Figure 3.3; Table 3.4).  Altogether, we 





fraction of bone marrow and spleen six days after infection with E. coli.   
 
Systemic E. coli infection dynamically affects HSPCs in bone marrow and spleen 
 
Having confirmed the surface marker profile of HSCs following infection, we 






 LSK) in 
bone marrow and spleen over twelve days of infection (Figure 3.4).  Although CD41 
expression on HSCs increases with age, it is very low on HSCs from young adult mice 
and its inclusion helps to exclude contaminating megakaryocytes (Kiel et al., 2005).  We 
observed moderate alterations in the surface marker profile of hematopoietic progenitors 
over twelve days of infection (Figure 3.4A and B).  E. coli infection resulted in transient 
bone marrow hypocellularity at days 3 and 6 that normalized by day 9 along with mild 




trended towards a reduction in the bone marrow at day 6 and recovered thereafter, while 
LSK cells in the spleen trended toward an increase at days 3 and 6 that diminished by day 






 LSK cells were reduced in the 







 LSK cells in the spleen were significantly increased at day 6, peaked by 
day 9 and began to diminish by day 12 (Figure 3.4G and H).  These results suggest that 
systemic infection induces a reduction and subsequent recovery of HSCs in bone marrow 
along with a delayed expansion of HSCs in the spleen.  
 
Expansion of splenic HSCs during infection is dependent on PRRs 
 
Systemic administration of LPS, which is sensed by TLR4, can promote 
extramedullary hematopoiesis in the spleen (Esplin et al., 2011; Vos et al., 1972), yet 
most preparations of LPS are contaminated with peptidoglycan that activate NLRs 
(Inohara et al., 2001).  To determine whether TLRs and NLRs play a role in driving the 











 mice before and 
after infection with E. coli (Figure 3.5A and B).  We did not observe any differences in 











 mice compared with uninfected WT mice (Figure 3.5A and 







cells in bone marrow of Ripk2
-/-
 mice three days after infection, but this was not observed 
in Tlr4
-/-



















 LSK cells in spleens Ripk2
-/-
 mice compared 







 LSK cells in spleens of Tlr4
-/-
 at any point during infection 
(Figure 3.5B).  These results implicate critical roles for TLR and NLR signaling in the 
expansion of extramedullary HSCs during infection.       
 
NOD1 and TLR4 signaling act synergistically to expand splenic HSCs 
 
To investigate whether activation of TLR and NLR signaling pathways are 






 LSK cells in spleen, we treated WT mice with 
either ultrapure LPS, which is devoid of contaminating peptidoglycan, or KF1B, a 
bacterial dipeptide that specifically activates NOD1 (Masumoto et al., 2006), or both 
(Figure 3.5C and D).  A single i.p. injection of ultrapure LPS or KF1B alone induced 






 LSK cells in bone marrow or 














 LSK cells in spleen after six days (Figure 3.5C and 
D), reminiscent of changes observed after E. coli infection.  To confirm that TLR4 and 
NOD1 stimulation expanded functional HSCs within the spleen, we treated WT (CD45.l) 
mice with PBS, LPS, KF1B or both and after six days mixed 1x10
6
 splenocytes with 
3x10
5
 untreated (CD45.2) WBM and transplanted these cells into lethally irradiated 




three independent experiments, splenocytes from LPS or KF1B treated spleens had on 
average 2.2-fold (4/9 LTMR) and 2.5-fold (4/10 LTMR) more RUs, respectively, than 
PBS treated spleen (2/12 LTMR), while splenocytes from LPS and KF1B had on average 
6.7-fold (7/12 LTMR) more RUs than PBS treated spleens, though these differences did 
not reach statistical significance due to high variability (Figure 3.5E and F).  These 
results support the conclusion that dual activation of TLR4 and NOD1 cooperate to 
expand the pool of functional HSCs in spleen. 
NOD1 signals via the adaptor protein RIPK2, whereas TLR4 signals via the 
adaptor proteins Myd88 and TRIF.  To determine which signaling pathways are 





















 LSK cells in the spleen after LPS and KF1B administration was 
dependent on RIPK2 and TRIF, but was inconclusive with respect to Myd88, since 
Myd88
-/-






 LSK cells at 
steady-state (Figure 3.5G and H).  These results confirm that KF1B-induced activation 
of NOD1 signals through the adaptor RIPK2 in this setting and suggests that TLR4 
signaling through TRIF is important for inducing the expansion of HSCs in the spleen.   
 
TLR4 expression on HSCs is not required for their expansion in spleen 
 
TLR4 is expressed on a subset of LSK cells (Nagai et al., 2006), yet it is unclear 




been proposed that Tlr4
-/-
 HSCs outcompete WT HSCs in competitive reconstitution 
assays (Ichii et al., 2010).  To test whether expression of TLR4 on HSCs influences their 
reconstitution ability, we transplanted lethally irradiated WT (CD45.1) mice with a 
mixture of 2.5x10
6




 (CD45.2) WBM and 
measured peripheral blood chimerism (Figure 3.6A and B).  After 16 weeks, myeloid 
reconstitution was equivalent between WT and Tlr4
-/-
 cells, while B-lineage 
reconstitution was unbalanced in favor of Tlr4
-/-
 cells and T-lineage reconstitution was 
unbalanced in favor of WT cells (Figure 3.6B). The differences in T-lineage 
reconstitution at early points after transplant could be due to a functional deficit of Tlr4
-/-
 
T-lineage progenitors or could reflect the presence long lived recipient-derived T-cells.  
These results indicate that Tlr4
-/-
 HSCs are functionally comparable to WT HSCs, but 
may harbor bias with respect to lymphoid reconstitution.   
To determine whether TLR4 expression on HSCs themselves was required for 







 LSK cells in bone marrow and spleen after six 









 LSK cells was roughly equivalent in bone marrow, consistent with our 









 LSK cells in the spleen (Figure 3.6C and D).  Conversely, in mice treated with 








 LSK cells were expanded in 
the spleen (Figure 3.6D).  To confirm these data functionally, we non-competitively 
transplanted 3x10
7
 splenocytes from PBS or LPS and KF1B treated mice into lethally 




(Figure 3.6E).  As expected, in recipients of PBS treated splenocytes, the majority of 
peripheral blood cells were WT derived, whereas in recipients of LPS and KF1B treated 
spleens, Tlr4
-/-
 and WT peripheral blood cells were roughly equivalent (Figure 3.6E).  
These data indicate that expression of TLR4 on HSCs is not required for their 
accumulation in spleen after TLR4 and NOD1 stimulation. 
 
NLR and TLR signaling in the radio-resistant compartment is important for 
expansion of splenic HSPCs 
 
TLRs and NLRs are expressed on a variety of hematopoietic and non-
hematopoietic cell types.  To determine which cellular compartment is required for 
mediating TLR and NLR induced expansion of HSPCs, we generated reverse chimeras 




 mice was transplanted into 




 recipients and were allowed to recover for at 
least 16 weeks.  Chimeric mice were administered LPS and KF1B and after six days 
splenocytes were plated in Methocult 3434 medium to quantify myeloid and erythroid 
progenitors.  The expansion of myeloid and erythroid progenitors in WT recipients 
transplanted with WT WBM was comparable to similarly treated non-irradiated WT mice 
(Figure 3.6F and G).  Ripk2
-/-
 recipients of Ripk2
-/-
 WBM and Tlr4
-/-
 recipients of Tlr4
-/-
 
WBM exhibited blunted expansion of myeloid and erythroid progenitors in spleen, 
consistent with a requirement for both TLR and NLR signaling in promoting 
extramedullary HSPC expansion (Figure 3.6F and G).  Notably, expansion of myeloid 












 mice that received WT 
WBM exhibited reduced expansion of myeloid and erythroid progenitors compared to 
WT controls (Figure 3.6A and B).  These results indicate that TLR and NLR signaling in 
radio-resistant cells, but not radio-sensitive cells are required for expansion of HSPCs in 
the spleen and suggest that indirect factors are involved.  
 
G-CSF signaling is required for NLR and TLR induced expansion of splenic HSCs 
 
Repeated administration of G-CSF induces the mobilization of HSCs from bone 
marrow to peripheral blood and spleen in both mouse and man (Duhrsen et al., 1988; 
Molineux et al., 1990; Morrison et al., 1997).  Systemic administration of LPS can 
increase G-CSF in the serum (Hareng and Hartung, 2002), but a role for endogenous G-
CSF in LPS-induced extramedullary hematopoiesis has not been addressed.  We found 
that i.p. injection of WT mice with ultrapure LPS resulted in massively increased levels 
of G-CSF in serum by 4 hours (186.2 ± 118.2 ng/mL) compared with KF1B (1.2 ± 0.3 
ng/mL) or PBS (0.3 ± 0.1 ng/mL), and the level of G-CSF was synergistically enhanced 
with dual administration of LPS and KF1B (488.0 ± 50.0 ng/mL) (Figure 3.7A).  
Treatment of Nod1
-/-
 mice with LPS and KF1B resulted in G-CSF levels (145.5 ± 164.9 
ng/mL) similar to WT mice treated with LPS alone, confirming that KF1B acts 
exclusively through NOD1 (Figure 3.7A).     
To test whether G-CSF was required for HSC accumulation in spleen, we injected 
WT mice with G-CSF blocking antibody or isotype control one hour prior to injection 
























 LSK cells in spleen was reduced in mice pre-treated with G-CSF 
blocking antibody but not isotype control antibody (Figure 3.7B and C).  To test whether 




) mice with 







cells in spleens of these mice was almost completely blocked (Figure 3.7C).  Finally, 
downregulation of CXCL12 in bone marrow is a common feature of G-CSF-mediated 
mobilization (Levesque and Winkler, 2008; Petit et al., 2002) so we tested whether 
expression of CXCL12 was altered in the bone marrow after challenge with bacterial 
products.  Dual administration of LPS and KF1B resulted in reduced CXCL12 message 
in WBM after two days, while single administration of LPS or KF1B did not (Figure 
3.7D).  Thus, NOD1 and TLR4 act synergistically to induce HSC accumulation in the 




Here we have demonstrated that systemic infection with the gram negative 
bacterium Escherichia coli drives the expansion of long term multilineage repopulating 
HSCs in the spleen along with a reduction of HSCs in the bone marrow.  Fractionation 
and competitive transplantation of bone marrow and spleen cells from infected mice 















CD48 and Mac1, which was present in our Lineage cocktail, have been associated with 
activation of HSCs after treatment with the myeloablative drug 5-fuorouracil (Randall 
and Weissman, 1997; Venezia et al., 2004), suggesting that HSCs may be similarly 
affected during myeloablation and infection.  Alternatively, inflammation may promote 
the de-differentiation of progenitors into self-renewing HSCs, with expression of CD48 
and Lineage markers serving as a relic of their previously differentiated identity (Jopling 
et al., 2011).  Expansion of splenic HSCs following infection was largely dependent on 
TLR4 signaling and partially dependent on NLR signaling via the adaptor protein RIPK2.  
Importantly, administration of ultrapure LPS alone was not sufficient to expand HSCs in 
the spleen, whereas dual administration of LPS and the synthetic NOD1 agonist KF1B 
was sufficient to expand splenic HSCs.  Thus, our studies highlight a previously 
unappreciated role for NLR signaling in promoting extramedullary hematopoiesis in the 
context of infection.   
The discovery that LSK cells express TLR4 and TLR2 raised the possibility that 
HSPCs can directly sense bacterial infection leading to alterations in lineage output 
(Nagai et al., 2006).  A recent model proposed that during infection, inflammatory 
cytokines and bacterial components push HSCs to differentiate, while reductions in 
effector cell populations pull HSCs to differentiate (King and Goodell, 2011).  Using 
reverse chimeras, we showed that signaling through PRRs in radio-sensitive cells was not 
important for driving HSPC expansion in spleen.  Instead, TLR4 and NOD1 signaling in 
radio-resistant cells was sufficient to expand HSPCs in spleen.  Consistent with this, 
another group found that TLR4 expression in radio-resistant cells was critical for 




treatment (Boettcher et al., 2012).  To unequivocally test whether TLR4 expression was 
required for HSC expansion in spleen, we generated chimeric mice with similar numbers 
of WT and Tlr4
-/-
 derived hematopoietic cells.  In these mice, Tlr4
-/-
 HSCs expanded in 
the spleen after TLR4 and NOD1 stimulation and gave rise to progeny in irradiated 
recipients over 16 weeks.  Altogether, our results strongly support a role for radio-
resistant cells in driving the expansion of HSCs in spleen after PRR stimulation and 
indicate that TLR4 expression on HSCs is dispensable in this setting. 
It is well established that repeated administration of recombinant G-CSF 
mobilizes functional HSCs from the bone marrow to blood and spleen (Duhrsen et al., 
1988; Molineux et al., 1990; Morrison et al., 1997).  Synergistic production of G-CSF 
following TLR4 and NOD1 activation correlated with downregulation of CXCL12 in the 
bone marrow and accumulation of HSCs in the spleen that was inhibited with either G-
CSF blocking antibody or lack of the G-CSF receptor.  These results suggest that 
mobilization of HSCs from bone marrow to the spleen may be responsible for the 
observed expansion of splenic HSCs during infection.  Alternatively, since a small 
population of functional HSCs exists in the spleen under steady-state conditions (Morita 
et al., 2011), we cannot rule out the possibility that local proliferation also contributes to 
expansion of splenic HSCs during infection.   
The spleen can serve as a site for extramedullary hematopoiesis during periods of 
stress, yet the spleen is not required for survival.  The biological significance for an 
expanded pool of HSCs in the spleen during infection is not clear.  Some studies have 
proposed that bacterial infection or administration of LPS damages HSCs in the bone 




2009).  We observed a reduction of functional HSCs in bone marrow following E. coli 
infection along with expansion of functional HSCs in spleen.  It is possible that excessive 
inflammatory signaling within the bone marrow microenvironment might transiently 
compromise the bone marrow niche and egress of HSCs could serve as a protective 
mechanism until the infection is cleared and the bone marrow niche is repaired.   
Consistent with the notion that the bone marrow niche is altered during infection, 
we and others find that CXCL12 is downregulated in bone marrow after exposure to 
bacteria or their components (Delano et al., 2011; Johns and Borjesson, 2012; Ueda et al., 
2005).  Interestingly, CXCL12 also contributes to the retention of neutrophils in bone 
marrow and mobilization of neutrophils during polymicrobial sepsis is required for 
bacterial clearance and host survival (Delano et al., 2011).  Physiologic cycling of HSPCs 
in and out of the blood steam is influenced by the level of circulating neutrophils and 
removal of aged neutrophils by bone marrow macrophages promotes HSPC mobilization 
(Casanova-Acebes et al., 2013).  HSC egress during infection could merely represent a 
bystander effect secondary to an immediate requirement for peripheral granulocytes.  
Alternatively, given the immense need for cell replenishment during systemic infection, 
the splenic pool of HSCs may provide a lasting reservoir for effector cell production.  
This hypothesis is supported by work showing that HSCs traffic through peripheral tissue 
under steady-state conditions and that LPS can induce proliferation of HSPCs at local 
sites of inflammation (Massberg et al., 2007).  Compared with the bone marrow niche, 
which preserves HSCs in a highly quiescent state, the splenic niche may provide a micro-




expansion of the splenic pool of HSCs may be important for limiting subsequent 
infections or providing a protective niche for HSCs during periods of stress.   
The expansion of HSCs in the spleen during bacterial infection highlights the 
dynamic nature of stem cells and their niche(s) in the setting of stress.  Our results 
support the hypothesis that direct sensing of infection by HSCs is not important for 
promoting extramedullary hematopoiesis.  Rather, the initiation of extramedullary 
hematopoiesis during infection is more likely a consequence of alterations in the HSC 
microenvironment.  A better understanding of the signals that influence HSCs and their 
niche(s) during infection may lead to improved methodologies for isolation and 
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Figure 3.3 │ All HSC activity exists in the cKit+ Sca1+ fraction of bone marrow and spleen after 
infection  
(A-F) Wild type (CD45.1) mice were injected with ~1x10
8
 E. coli K12 i.p and after 6 days, (top) bone 
marrow or (bottom) spleen cells were sorted and resorted based on positive or negative expression of 
(A, B) Lineage (CD3, CD4, CD8, B220, Ter119, Gr-1, Mac1) (C, D) Sca1 or (E,F) cKit.  (B, D, F) Positive or 
negative fractions from (top) bone marrow or (bottom) spleen were mixed with 3x10
5
 whole bone 
marrow from WT (CD45.2) mice and transplanted into lethally irradiated (CD45.2) recipients.  
Peripheral blood chimerism of Myeloid (Mac1+), B-lineage (B220+) and T-lineage (CD3+) cells were 
































Table 3.1  Antibodies used in flow cytometry   
Target Clone Company Conjugate(s) Dilution Time 
      
CD3e 145-2C11 BioLegend FITC, PE 1:200 25 mins 
CD4 GK1.5 eBiosciences FITC 1:200 25 mins 
CD8 53-6.7 eBiosciences FITC 1:200 25 mins 
B220 RA3-6B2 eBiosciences FITC, PE-Cy5 1:200 25 mins 
Gr-1 RB6-8C5 BioLegend FITC, PE-Cy7 1:200, 1:600 25 mins 
Mac1 (CD11b) M1/70 eBiosciences FITC, APC 1:200, 1:400 25 mins 
TER119 TER119 BioLegend FITC 1:200 25 mins 
Lineage panel 
(CD3e, B220, Mac1, 
Gr-1, TER119) 
eBiosciences Biotin 1:200 
20 mins, 
1.5 hrs 
CD4 GK1.5 BioLegend Biotin 1:400 
20 mins, 
1.5 hrs 
CD8 53-6.7 BioLegend Biotin 1:400 
20 mins, 
1.5 hrs 
CD150 TC15-12F123.2 BioLegend PE 1:200 
20 mins, 
1.5 hrs 
CD48 HM48-1 BioLegend FITC, PE-Cy7 1:200 
20 mins, 
1.5 hrs 
CD41 MWReg BioLegend FITC, PE-Cy7 1:200 
20 mins, 
1.5 hrs 
Sca1 E13-161.7 BioLegend PE-Cy7, APC 1:200 
20 mins, 
1.5 hrs 
cKit 2B8 BioLegend APC-Cy7 1:200 
20 mins, 
1.5 hrs 
CD34 RAM34 eBiosciences FITC 1:50 1.5 hrs 
CD45.1 A20 BioLegend APC-Cy7 1:200 25 mins 

















Percentages represent the average of each gated population in bone marrow or spleen of 
mice that were infected six days prior with E. coli.  The number of cells to inject (along 
with 3x10
5
 congenic WBM) was calculated by multiplying the percentage of the gated 
population by 3x10
5
 for bone marrow and by 2x10
6














Table 3.2  Summary of cells injected for Figures 3.2 and 3.3 
  Avg. % within infected tissue  Number of cells injected 
  Bone marrow Spleen  Bone marrow Spleen 
Population  + - + -  + - + - 
CD150  4 94 60 36  1 x 10
4
 2.8 x 10
5
 1.2 x 10
6
 7 x 10
5
 
CD48  33 54 81 14  1 x 10
5
 1.6 x 10
5
 1.6 x 10
6
 3 x 10
5
 
Lineage  98 1.1 96 3  2.9 x 10
5
 3 x 10
3
 1.9 x 10
6
 6 x 10
6
 
Sca1  1.8 78 22 53  5 x 10
3
 2 x 10
5
 4 x 10
5
 1 x 10
6
 
cKit  1.8 96 1.5 98  5 x 10
3
 2.9 x 10
5
 3 x 10
4













My (Avg. %) BC (Avg. %) TC (Avg. %) 
       
CD150+ Bone 
Marrow 
4 8/10 41 29 1 
8 10/10 24 29 23 
12 10/10 27 30 34 
16 10/10 20 27 33 
      
Spleen 4 7/7 23 20 7 
8 7/7 28 26 24 
12 7/7 25 28 28 
16 7/7 21 28 28 
       
CD150- Bone 
Marrow 
4 6/9 2 17 4 
8 2/9 0.2 4 7 
12 1/9 0.2 2 5 
16 0/9 0.1 1 4 
      
Spleen 4 5/9 2 31 8 
8 3/9 0.5 5 8 
12 2/9 0.2 4 5 
16 0/9 0.1 3 4 
       
CD48+ Bone 
Marrow 
4 3/10 11 24 0.8 
8 5/10 2 10 6 
12 3/10 0.6 7 10 
16 2/10 0.2 5 7 
      
Spleen 4 10/10 10 39 6 
8 7/10 2 10 10 
12 5/10 3 8 8 
16 2/10 2 7 7 
       
CD48- Bone 
Marrow 
4 5/10 28 25 0.5 
8 9/10 18 20 14 
12 9/10 23 18 19 
16 7/10 18 16 16 
      
Spleen 4 5/10 30 18 1 
8 9/10 24 26 23 
12 9/10 16 24 28 












My (Avg. %) BC (Avg. %) TC (Avg. %) 
       
Lineage+ Bone 
Marrow 
4 0/5 6 6 0 
8 3/5 6 6 2 
12 3/5 6 6 2 
16 3/5 3 7 4 
      
Spleen 4 0/5 0.2 3 2 
8 1/5 0.4 0.3 2 
12 0/5 0.8 0.9 2 
16 0/5 0.8 0.2 2 
       
Lineage-/lo Bone 
Marrow 
4 3/5 36 23 4 
8 5/5 23 21 18 
12 5/5 9 14 19 
16 5/5 4 12 18 
      
Spleen 4 3/5 14 17 3 
8 5/5 15 10 11 
12 5/5 9 10 10 
16 5/5 8 11 13 
       
Sca1+ Bone 
Marrow 
4 4/5 36 36 0.7 
8 5/5 29 27 22 
12 5/5 16 23 21 
16 5/5 11 24 24 
  3/3    
Spleen 4 3/3 29 17 5 
8 3/3 22 19 18 
12 3/3 11 17 18 
16 3/3 11 18 21 
       
Sca1- Bone 
Marrow 
4 0/5 0.6 2 1 
8 1/5 0.3 0.9 1 
12 0/5 0 0.1 0.5 
16 0/5 0 0.1 0.6 
      
Spleen 4 2/5 0.8 2 0.8 
8 1/5 0.1 0.2 0.6 
12 0/5 0.3 0.1 0.2 
16 0/5 0.1 0.1 0.2 
       
cKit+ Bone 
Marrow 
4 5/5 34 41 5 
8 5/5 38 38 25 
12 5/5 33 38 33 
16 5/5 25 38 42 
      
Spleen 4 5/5 43 57 4 
8 5/5 33 62 43 
12 5/5 38 61 51 
16 5/5 38 63 58 
       
cKit- Bone 
Marrow 
4 0/5 0.1 0.2 0 
8 1/5 1 0.5 0.2 
12 0/5 0.2 0.1 0 
16 0/5 0.2 0.8 0.1 
      
Spleen 4 0/5 0.1 1 1 
8 0/5 0.1 0.1 0.6 
12 0/5 0.2 0.3 0.8 









 Sensing of foreign entities by pattern recognition receptors is a crucial component 
of the innate immune system.   Recognizing infectious stimuli is essential for mounting 
appropriate immune responses, yet deregulation of PRR signaling can result in 
autoimmunity, such as NOD2 mutations predisposing to Crohn’s disease.  How 
aberrations in NOD2 signaling lead to CD requires further investigation.  Intriguingly, 
PRRs have been implicated in the regulation of hematopoietic progenitors, including 
hematopoietic stem cells, following exposure to infectious agents.  Given the necessity 
for cell production during infection, it follows that stem cell activity may be altered to 
meet the increasing demands, yet mechanisms underlying the response of HSCs to 
infection remain elusive.  This thesis takes both a global approach to identify novel 
networks of genes involved in regulation of the NOD2 signaling pathway as well as a 
targeted approach to understand how PRR signaling influences cells at the apex of the 
hematopoietic hierarchy.  Together, these results shed light on the diversity of pathways 
that regulate and are regulated by PRR signaling and offer insight into mechanisms that 





Insights into the pathogenesis of Crohn’s disease 
 
 The first definitive description of Crohn’s disease (originally termed Regional 
Ileitis) was published in 1932 (Crohn et al., 1932).  In that landmark article, the authors 
defined the features of disease to include isolated regions of intestinal inflammation 
primarily occurring in the terminal ileum that span the entire thickness of the digestive 
tube, which frequently contained granulomas and fistulas linking bowel sections and 
often resulted in abdominal pain, diarrhea, bowel obstruction and emaciation (Crohn et 
al., 1932).  Though the physical parameters of disease were clear, the underlying cause 
was elusive.  Crohn stated: 
In a disease of this type, in which an attempt is being made to establish the 
etiology of the disease, we have naturally taken great pains to exclude every 
known etiologic factor.  Histologic sections were made of the tissues and stained 
with various types of stains.  Cultures were made.  Ground material was injected 
into guinea-pigs and fowl.  Various types of laboratory animals were used to 
eliminate any possible form of tuberculosis.  Löwenstein cultures were made.  Dr. 
Klemperer, the pathologist, exhausted all the known possible scientific methods of 
finding an etiologic factor.  I can say that no etiologic factor was found.   
 
Since that seminal description, much has been learned regarding the pathogenesis of CD 
(Baumgart and Sandborn, 2012), but the full spectrum of contributing features remains to 
be uncovered.   
Strong evidence for a genetic contribution to CD came from studies showing 
higher incidence of disease in monozygotic twins (which have essentially identical 
genomic makeup) versus dizygotic twins (which share on average half of their genetic 
makeup) as well as the tendency for disease to occur in multiple family members 
(Orholm et al., 1991; Tysk et al., 1988).  Even before the identification of specific genes, 




in promoting remission of CD indicated that interactions between immune cells and the 
microbiota play an important role in CD pathogenesis  (Fiocchi, 1998; Selby, 2000).  The 
discoveries that (1) NOD2 polymorphisms predispose to CD, that (2) NOD2 is important 
for sensing components of bacteria and activating pro-inflammatory signaling cascades 
and that (3) CD-associated NOD2 mutations render it inactive, all supported a central role 
for NLR signaling in balancing protection and autoimmunity at the intestinal interface 
(Hugot et al., 2001; Inohara et al., 2003; Ogura et al., 2001a).  Accordingly, we 
hypothesized that a comprehensive understanding of genes that regulate NOD2 signaling 
would yield insight into the mechanisms underlying CD pathogenesis.  
In Chapter II, I described the results of a genome-wide screen analyzing the 
influence of individually knocking down just over 18,000 genes on NOD2-induced NF-
κB activation.  The screen was performed using HEK293 cells stably expressing human 
NOD2 and a NF-κB luciferase reporter gene.  By measuring viability using a 
fluorescence based assay and NF-κB luciferase in tandem, we were able to discriminate 
between genes that genuinely altered NOD2 signaling from those that negatively affected 
cell number.  Using this strategy, we identified multiple core components of the 
NOD2/NF-κB signaling pathway including NOD2, RIPK2, NEMO and RELA as well as 
components of the proteasome, which is required for degradation of the inhibitory protein 
IκB that restricts NF-κB in the cytoplasm, and components of the nuclear pore, which is 
essential for nuclear translocation of NF-κB following its release.  These findings verified 
that our screen was capable of uncovering genes important for many different stages of 
NOD2 signaling and supported roles for novel genes identified as positive or negative 




One of our original goals was to identify genes that were specifically required for 
NOD2 signaling.  Having identified numerous putative NOD2 regulators in our primary 
screen, we proceeded to conduct a secondary counter screen using independent siRNA 
pools to control for off target effects.  To distinguish between NOD2 specific regulators 
and general regulators of NF- κB, we stimulated our reporter cells with either MDP or 
TNFα, which activates NF-κB transcription independently of NOD2 (Aggarwal, 2003).  
Results from the counter screen revealed that nearly all the validated regulators 
influenced both MDP- and TNFα-induced NF-κB activation.  We therefore concluded 
that the immune system largely relies on a few upstream sensors and adaptors that 
converge on common NF-κB transcriptional machinery.  Because NOD2 mutations, but 
not TNFα or TLR mutations, are strongly linked to CD, it is likely that the cellular 
context in which the pro-inflammatory signaling pathways are activated play a large role 
in the effect of each regulatory gene on disease.   
One example of the importance of context can be illustrated by Paneth cells, 
which express NOD2 (Ogura et al., 2003).  Paneth cells are located in the crypts of 
Lieberkühn within the small intestine and contribute to intestinal barrier defense through 
the secretion of antimicrobial peptides (AMPs) (Baumgart and Sandborn, 2012; Clevers 
and Bevins, 2013).  AMPs limit the translocation of bacteria from the gut lumen to the 
underlying mucosa by direct microbicidal activity and formation of nanonets (Chu et al., 
2012; Ouellette, 2011; Wu et al., 2004).  Disruption of Paneth cells and reduction of 
AMPs is a common feature in CD patients, especially those with inactivating NOD2 
mutations (Wehkamp et al., 2004; Wehkamp et al., 2005).  Since our screen was 




identified as NOD2 regulators also function in Paneth cells to regulate AMP secretion.  
The lack of Paneth cell-specific cell lines limits the ability to perform a complementary 
genome-wide screen and likely necessitates that any putative regulators of AMP 
production be verified in vivo.  A reasonable strategy would be to compare our list of 
NOD2 regulators with a list of genes expressed in Paneth cells by micro-array thereby 
reducing the number of genes to focus on for time consuming and costly follow-up 
studies. 
Our screen identified numerous genes that were previously associated with CD 
risk as being NOD2 regulators, supporting a role for members of the NOD2 signaling 
pathway, beyond just NOD2, in the pathogenesis of CD. This idea is further supported by 
the fact that a subset of CD patients exhibit impaired MDP responses in the absence of 
NOD2 mutations (Seidelin et al., 2009). Furthermore, over 1000 CD susceptibility loci 
have been discovered, yet only 71 loci have been assigned to a specific gene (Barrett et 
al., 2008; Franke et al., 2010; Rivas et al., 2011), highlighting the need to define 
causative factors at these unassigned loci.  One potential application of our data set is in 
overlapping our list of NOD2 regulators with genome-wide association studies and next-
generation DNA sequencing to explore the genetic basis of CD.  In risk loci containing 
multiple genes, our data set could assist in the selection of candidate genes for future 
hypothesis based studies.  Moreover, it is likely that many unidentified risk loci are 
partially penetrant and only present in a small number of diseased individuals, making it 
difficult to obtain statistical significance on a genome-wide scale.  By limiting the 
analysis to SNPs within exons or promoter regions of genes identified in our screen, we 




Consequently, the lack of association in current studies should not invariably exclude a 
role for a particular gene in CD pathogenesis.   
One example of a gene not previously implicated in CD risk is neutrophil 
cytosolic factor 1 (NCF1), a member of the NADPH oxidase complex that functions to 
generate reactive oxygen species (ROS) in phagocytes (Bedard and Krause, 2007), which 
was identified and validated as a positive regulator of NOD2 and TNFα signaling in our 
screens.  Although NCF1 has not previously been linked to CD, other NADPH oxidase 
components including NCF2 and NCF4 have been associated with CD (Muise et al., 
2012; Rioux et al., 2007).  Interestingly, inactivating mutations in Ncf1 sensitize rats and 
mice to experimental models of collagen-induced arthritis, while copy number variants of 
human NCF1 are linked to rheumatoid arthritis (Hultqvist et al., 2004; Olofsson et al., 
2003; Olsson et al., 2012).  Furthermore, mutations in NCF1 and other components of the 
NADPH oxidase complex are the etiologic agent in chronic granulomatous disease, a 
disorder in which phagocytes from affected patients are unable to kill ingested bacteria 
and which shares some pathological features with CD (Francke et al., 1990; Marks et al., 
2009).  Together, these findings indicate that components of the NADPH oxidase 
machinery play an important role in immunity and resistance to autoimmune disease.   
A common criticism of genome-wide screens concerns the use of highly 
transfectable immortalized cell lines, such as HEK293, that may not represent the 
physiologic context of the signaling pathway being analyzed.  To address this concern, 
we tested whether NCF1 was important for NOD2 signaling in bone marrow derived 
macrophages in which NOD2 is known to function in vivo.  When WT and Ncf1
-/-
 




levels of phosphorylated IκB (p-IκB) in Ncf1
-/-
 and WT cells, total IκB protein was not 
diminished in Ncf1
-/-
 cells. Since phosphorylation of IκB typically precedes its 
degradation and subsequent release of NF-κB from negative regulation, this finding 
suggests that NCF1 influences the recognition and degradation of p-IκB.  This regulation 
was specific to NF-κB, since MAPK signaling was unperturbed in Ncf1
-/- 
macrophages 
stimulated with MDP.  Multiple molecular mechanisms could explain these results and 
require further exploration.  One hypothesis is that NCF1 may be important for 
trafficking of p-IκB to the proteasome.  This could be tested using confocal microscopy 
of WT and Ncf1
-/- 
macrophages stimulated with MDP to track the intracellular location of 
p-IκB in relation to the proteasome.  Alternatively, NCF1 may promote the dissociation 
of p-IκB from NF-κB to facilitate IκB degradation.  This could be assessed by stimulating 
WT and Ncf1
-/- 
macrophages with MDP and immunoprecipitating p-IκB, followed by 
western blotting for NF-κB.  Lastly, NCF1 could be essential for proteasome function 
itself.  To address this, WT and Ncf1
-/- 
macrophages could be stimulated with interferon 
gamma followed by western blotting to measure JAK2 degradation, which is also 
dependent on the proteasome (Ungureanu et al., 2002).  Regardless of the mechanism, 
these results are consistent with a role for NCF1 in promoting the activation of NF-κB, 
but not MAPKs, downstream of NOD2 signaling.   
How might a requirement for NCF1 in NOD2/NF-κB signaling affect CD 
susceptibility?  Phagocytes deficient in ROS production are more likely to harbor viable 
intracellular bacteria (Jackson et al., 1995).  If NCF1 is perturbed by mutation or 
inactivation, it may be advantageous to limit pro-survival signals emanating from NF-κB 




chemokines downstream of MAPKs.  Apart from their role in destroying bacteria, ROS 
are also important for suppressing immune responses through inactivation of pro-
inflammatory molecules in the extracellular milieu (Harrison et al., 1999).  Alteration of 
NCF1-mediated ROS production could therefore contribute to perpetuation of 
inflammatory conditions in CD patients.  Of note, pharmacological induction of ROS was 
able to prevent disease in a model of arthritis driven by inactive NCF1 (Olofsson et al., 
2003).  Thus, drugs promoting NCF1 and ROS production may represent novel 
therapeutic strategies for treating CD and warrants further investigation. 
Using an unbiased genome-wide screening approach, we have identified and 
validated over 200 positive and negative regulators of the NOD2/NF-κB signaling 
pathway.  By overlapping these genes with publicly available protein-protein interaction 
databases, we were able to visualize novel networks of regulatory complexes.  Many 
genes within these complexes had previously been linked to CD, reinforcing a critical 
role for NOD2 and NF-κB in susceptibility to this disease.  In total, our results provide a 
platform to understand how aberrant NOD2 signaling predisposes to autoimmunity and 
helps to generate novel hypotheses to investigate the pathogenesis of CD. 
 
A role for extramedullary hematopoietic stem cells during infection 
 
Hematopoiesis is sustained throughout life by a small pool of self-renewing 
hematopoietic stem cells.  Adult HSCs typically reside in specialized niches within the 
bone marrow where a complex milieu of supporting cells, extracellular matrix 




persistence.  Disruption of the niche through genetic ablation of essential genes, 
pharmacologic activation of niche cells or exogenous administration of mobilizing agents 
can indirectly influence the behavior and localization of HSCs.  Cell intrinsic 
mechanisms such as regulation of the cell cycle and responsiveness to extracellular cues 
are also important for regulating HSC function.  Investigating the physiologic signals that 
affect HSCs under homeostatic and stressful conditions is critical for understanding how 
HSCs contribute to disease states and for improving HSC utility in the clinic.  As 
bacterial infection is a physiologically relevant stressor that can have profound effects on 
the hematopoietic system and is common in recipients of hematopoietic transplants in the 
clinic, it serves as a useful tool to investigate the mechanisms governing HSC responses 
when homeostasis is disrupted.   
A central unresolved question in stem cell biology is whether the function of long 
term multilineage repopulating HSCs is altered in the context of infection. Previous 
reports have offered conflicting and often inconclusive results.  Using a model of 
systemic LPS challenge followed by transplantation of bone marrow-derived LSK cells, 
one study found that HSC function was markedly reduced (Rodriguez et al., 2009), 
whereas another study found that HSC function was enhanced (Takizawa et al., 2011).  
Another group infected mice with Mycobacterium avium and transplanted bone marrow-
derived LSK cells capable of excluding Hoechst dye and observed a massive reduction in 
HSC function compared to uninfected cells (Baldridge et al., 2010).  The interpretation of 
these results is complicated by the possibility that surface markers or dye exclusion 
properties used to isolate HSCs under steady-state conditions may be altered following 




population.  Other studies have circumvented this limitation by transplanting 
unfractionated bone marrow cells from mice treated with LPS and found that total HSC 
activity in bone marrow was reduced under those conditions (Chen et al., 2010; Esplin et 
al., 2011).  Still, it is debatable whether the concentrations of LPS used in those studies 
accurately reflect the physiological context of live bacterial infection.  Moreover, none of 
those studies tested whether HSC activity is altered in sites outside the bone marrow, 
which might shed light on some of the observed results.  Thus, an unbiased functional 
characterization of HSC activity in the bone marrow and periphery following live 
bacterial infection was required to resolve this controversy.   
In Chapter III, I described the functional characterization of murine HSCs 
following systemic infection with the gram negative bacterium Escherichia coli K12.  
We selected this bacterium because intraperitoneal administration did not result in 
lethality, supporting our goal to understand the physiologically relevant responses of 
HSCs to infection.  Competitive transplantation of unfractionated bone marrow or 
splenocytes from mice that had been infected for six days revealed that total HSC 
activity, which we defined as myeloid and lymphoid reconstitution over sixteen weeks, 
was reduced by approximately 2-fold in the bone marrow, whereas total HSC activity in 
the spleen was increased nearly 40-fold.  From this we concluded that infection with E. 
coli resulted in moderate reduction of HSC activity in the bone marrow coupled with 
robust expansion of extramedullary HSC activity. 
The systemic dissociation of microbes can promote a condition termed sepsis, in 
which recognition of microbial products in the blood results in the overwhelming 




2002).  Following the immediate systemic inflammatory response, a compensatory anti-
inflammatory response develops, which is characterized by excessive production of anti-
inflammatory cytokines, decreased numbers of immune cells and enhanced susceptibility 
to secondary infection (Ward et al., 2008).  Indeed, patients that survive systemic 
infection exhibit increased risk of mortality for years beyond the initial septic insult (Perl 
et al., 1995).  Given these lasting effects, it has been suggested that epigenetic alterations 
that diminish HSC function might contribute to perpetual immune deficiencies following 
sepsis (Carson et al., 2011).  Additionally, it has been proposed that the reduction of HSC 
activity in the bone marrow following administration of LPS is a consequence of cellular 
damage induced either by LPS itself or inflammatory cytokines that are produced during 
infection (Chen et al., 2010; Esplin et al., 2011).  It would be interesting to determine 
whether HSC activity in the bone marrow is irreparably altered following systemic 
infection or whether HSC activity is eventually restored, supporting alternative 
mechanisms for the observed immunodeficiencies.   
One limitation of the competitive transplantation assay is that it measures total 
HSC activity within a test population, but does not distinguish between the number of 
HSCs within that population and the function of each HSC.  Thus, the 2-fold reduction of 
HSC activity observed in bone marrow could represent a 2-fold reduction of total self-
renewing HSCs or a 2-fold reduction in the ability of each HSC to give rise to progeny in 
an irradiated host, or some combination of these factors.  The inverse could also be 
argued for the increased HSC activity we observed within infected spleen, although it 
seems unlikely that the robust expansion of extramedullary HSC activity following 




number of HSCs in bone marrow and spleen after infection, limiting dilution assays could 
be performed in which three doses of unfractionated WBM or splenocytes are 
competitively transplanted into irradiated recipients.  Using Poisson statistics it is 
possible to extrapolate the number of HSCs within each tissue from the fraction of 
recipient mice that are not reconstituted at each dose (Szilvassy et al., 1990).  If the total 
number of HSCs in the bone marrow had not changed following systemic E. coli 
infection, this would support the hypothesis that HSCs are damaged following infection.  
An observation of fewer bone marrow HSCs and greater splenic HSCs after infection 
would support the hypothesis that HSCs are not damaged during infection and are merely 
relocated to sites other than the bone marrow.   
A pitfall of the limiting dilution assay is that it cannot account for the number of 
HSCs that engraft a particular recipient mouse; it only determines whether a mouse was 
engrafted or not and therefore is uninformative for comparing the function of individual 
HSCs within the test population.  HSCs from unmanipulated bone marrow and spleen 
have been shown to be functionally comparable by sorting and competitively 
transplanting individual cells based on their surface marker expression (Morita et al., 
2011).  To compare HSCs from the bone marrow and spleen of infected mice using this 
assay, it is essential to verify that the surface markers used to sort HSCs are not altered.  
Therefore, we rigorously tested whether functional HSCs are contained within 
established surface marker profiles by sorting and competitively transplanting bone 
marrow and splenocytes from infected mice based on positive or negative expression of 
CD150, CD48, Lineage, cKit and Sca1.  We found that while all HSC activity was 














, subsets of HSCs in the bone marrow expressed CD48 
and Lineage markers and a subset of splenic HSCs expressed CD48.  These findings 
illustrate the need to validate new surface markers that can be used to enrich for all 
functional HSCs in the context of infection.  Since the majority of HSC activity was 










 population after infection, this 
combination of markers was still useful to interpret the dynamics of HSC localization.  
 To better understand how HSC populations changed during infection, we 






 LSK cells at various times after infection.  
CD41 was included in our staining cocktail to exclude contaminating megakaryocytes 






 LSK cells 







 LSK cells in spleen that reached an apex nine days after infection.  
This kinetic could support a model in which bacterial infection drives the mobilization of 
HSCs from the bone marrow through the blood stream to the spleen, but given the 
presence of local splenic HSCs under steady-state conditions, these kinetics do not 
distinguish between mobilization and local proliferation.  To unequivocally test whether 
HSCs are mobilized following infection, congenic mice could be linked by parabiosis and 
after a shared circulatory system is established one mouse could be challenged with E. 
coli. After six days of infection, the mice could be separated and allowed to recover for 
sixteen weeks.  If HSCs from the infected mouse were mobilized to the blood stream, a 
proportion would have engrafted the connected mouse and given rise to differentiated 
progeny.  If the expansion of splenic HSCs was entirely due to local proliferation, then 




of mice separated without infection.  Furthermore, if the results suggest that mobilization 
had occurred, it would be interesting to measure the proportion of foreign HSC activity in 
the bone marrow and spleen of the previously conjoined mouse, which would offer 
insight into the long term residency of mobilized HSCs.   
Infection results in the enhancement of extramedullary HSC activity, yet it is 
unclear whether peripheral HSCs play an important role in biology.  One possibility is 
that mobilization of HSCs is merely a secondary consequence of an essential requirement 
to mobilize neutrophils in order to clear the systemic infection.  Indeed, both neutrophils 
and HSCs are retained in the bone marrow by CXCL12/CXCR4 signaling and can be 
rapidly mobilized by systemic administration of the inflammatory cytokine IL-8 (Delano 
et al., 2011; Laterveer et al., 1996; Sugiyama et al., 2006).  Moreover, intravenous 
injection of neutrophils is sufficient to mobilize hematopoietic progenitors to the blood 
and reduce CXCL12 in the bone marrow, while antibody mediated depletion of 
neutrophils reduces circulating HSCs and increases CXCL12 expression in bone marrow, 
indicating that trafficking of neutrophils and HSCs are tightly correlated (Casanova-
Acebes et al., 2013).  A reasonable experiment would be to test whether infection 
expands extramedullary HSC activity in the absence of neutrophils or in the presence of 
some factor that blocks neutrophil egress from the bone marrow.   
Regarding a biological role for extramedullary HSCs, one group suggested that 
HSCs can localize to sites of inflammation and differentiate into type 2 macrophages to 
help resolve toxic liver injury (Si et al., 2010), while another group proposed that HSCs 
traffic through peripheral tissues in order to provide a local source of effector cells 




maintain HSCs long term, mobilization during infection may be an important mechanism 
to relocate these powerful cells to a specialized niche where alternative functions, such as 
symmetric self-renewal divisions that support lasting cell production, can be sustained.  
One prediction of this hypothesis is that the splenic HSC niche is expanded during 
infection.  Alterations in the splenic HSC niche could be visualized by administering E. 
coli to mice in which a fluorescent protein is expressed under the endogenous promoter 
of SCF or CXCL12 (Ding and Morrison, 2013; Ding et al., 2012; Greenbaum et al., 
2013).  Moreover, one could sort HSCs from the spleen or bone marrow of E. coli 
infected mice and transplant them into a mouse challenged with a lethal model of sepsis, 
such as cecal ligation and puncture, to determine whether peripheral HSCs are better 
suited to protect the injured host and to maintain cell production beyond the resolution of 
infection.   
 
Pattern recognition receptors promote extramedullary hematopoietic stem cell 
expansion indirectly    
 
Escherichia coli contain LPS and peptidoglycan that are recognized by TLR4 and 
NOD1/NOD2, respectively.  To test whether the expansion of extramedullary HSCs was 




 mice with E. coli and found 






 LSK cells in the spleens 
of these mice was reduced compared to WT mice.  Whereas administration of ultrapure 
LPS was sufficient to produce hundreds of nanograms of G-CSF in the serum, it was 




KF1B did not substantially increase G-CSF in the serum and was also insufficient to 
expand HSC activity in the spleen, but dual administration of LPS and KF1B 
synergistically enhanced G-CSF in the serum and HSC activity in the spleen.  Using G-
CSF-neutralizing antibodies and mice deficient for the G-CSFR, we show that G-CSF is 
required for extramedullary HSC expansion following LPS and KF1B administration.  
Furthermore, by challenging chimeric mice with LPS and KF1B we determined that PRR 
signaling in radio-resistant cells was important for promoting the accumulation of 
hematopoietic progenitors in the spleen.  Together, these results demonstrate that 
recognition of bacterial components by TLRs and NLRs in radio-resistant cells are 
necessary and sufficient to expand extramedullary HSCs in the context of infection.  
Moreover, they suggest that contamination of LPS preparations with NLR-activating 
moieties likely contributed to the expansion of peripheral HSPCs that was described 
previously (Vos et al., 1972).      
How do TLR4 and NOD1 cooperate to induce extramedullary hematopoiesis?  
One possibility is that the amplitude or duration of G-CSF exposure following LPS is too 
weak to trigger release of HSPCs from the bone marrow.  The enhanced production of G-
CSF induced by the presence of both LPS and KF1B may be necessary to exceed a 
threshold required for mobilization.  This hypothesis is supported by the fact that 
repeated administration of G-CSF over 4-5 days is required to mobilize HSPCs (Petit et 
al., 2002).  G-CSF-induced mobilization involves multiple mechanisms, one of which 
involves downregulation of CXCL12 in cells of the bone marrow niche (Petit et al., 
2002).  We found that CXCL12 expression was reduced in the bone marrow two days 




is unclear whether downregulation of CXCL12 is purely a consequence of reaching a 
threshold of G-CSF activation or whether TLR4 and NOD1 provide complimentary 
signals in CXCL12-expressing cells to regulate transcription of this gene.  Intriguingly, 
G-CSF treatment has been associated with reduced clinical symptoms in some CD 
patients, which correlated with increased T regulatory cells and plasmacytoid dendritic 
cells at sites of inflammation (Guidi et al., 2008; Mannon et al., 2009).  Since many CD 
patients harbor mutations in NOD2, an interesting possibility is that reduced NOD2 
signaling could limit production of G-CSF, which may be important for mobilizing 
HSPCs to the site of infection where their progeny could contribute to clearance of 
bacteria and resolution of inflammation. 
Reverse chimera experiments highlighted a role for TLR and NLR signaling in 
radio-resistant cells to promote extramedullary hematopoiesis, but these experiments did 
not determine the exact identity or location of cells responsible for mediating the 
observed effects.  Thus, TLR4 and NOD1 could be acting either in the same cell or 
different cells, which could be present within the bone marrow or peripheral tissues.  To 
dissect which cell type is responsible for mediating the expansion of peripheral HSCs 
following TLR4 and NOD1 stimulation, one would need to generate mice carrying floxed 
alleles of TLR4 and NOD1, which could be selectively deleted using cell type specific 
promoters to drive cre recombinase.  Likely candidates to test are Col2.3 expressing 
osteoblasts, Tie2 expressing endothelial cells and Prx1 expressing mesenchymal 
progenitors that have been previously implicated in various aspects of the bone marrow 
niche, such as expression of CXCL12 (Ding and Morrison, 2013; Greenbaum et al., 




If TLR4 and NOD1 signaling are important within the bone marrow niche to 
promote HSC mobilization, it would be interesting to understand how PRR signaling 
regulates CXCL12 expression.  Classical NF-κB signaling has been shown to negatively 
regulate CXCL12 expression in cultured endothelial cells through inhibition of non-
canonical NF-κB-dependent transcription (Madge and May, 2010).  CXCL12 expression 
is enhanced under hypoxic conditions and this is dependent on Hif-1α (Ceradini et al., 
2004).  Since Hif-1α is an NF-κB target gene (Rius et al., 2008), it is possible that PRRs 
regulate CXCL12 expression through this pathway.  This hypothesis could be tested by 
culturing primary CXCL12-expressing cells from the bone marrow in the presence of 
LPS, KF1B or both and measuring CXCL12 expression by quantitative PCR and Hif-1α 
occupancy on the CXCL12 promoter by chromatin immunoprecipitation.  Another 
interesting possibility is that PRR signaling in the spleen is important for recruiting 
HSCs.  Activation of TLR4 and subsequent production of G-CSF may be sufficient to 
mobilize HSCs from the bone marrow to the blood stream, but NOD1 signaling could be 
required to activate adhesion molecules on splenic endothelial cells to trap circulating 
HSCs.  To support this mechanism, one would need to identify an adhesion molecule that 
is induced on splenic endothelial cells following NOD1 (or NOD1/TLR4) activation and 
block this interaction with an antibody to show that HSC recruitment to the spleen is 
diminished.   
A major finding of our work was that TLR4 expression on HSCs is not required 
for their expansion in spleen following LPS and KF1B stimulation.   A subtle, yet notable 
finding was that Tlr4
-/-
 HSCs were not present in the spleens of irradiated mice that 
received equal numbers of WT and Tlr4
-/-




interpretation of this finding is that Tlr4
-/-
 HSCs preferentially localize to the bone 
marrow or fail to localize to the spleen when transplanted into an irradiated host.  These 
possibilities could be dissected by transplanting equal numbers of sorted WT and Tlr4
-/-
 
HSCs and measuring their numbers in bone marrow and spleen after a few hours.  If WT 
and Tlr4
-/-
 HSCs have similar capacity to localize to the spleen after transplantation, this 
would suggest that Tlr4
-/-
 HSCs compete poorly with WT HSCs for limited niches within 
the spleen and transit back to the bone marrow over time. To directly test whether TLR4 
deficient HSCs compete poorly with WT HSCs for splenic niches, one could transplant 
equal numbers of cells from WT and TLR4
fl/fl
 mice into irradiated recipients and measure 
HSC residency in the spleen after inducible deletion of TLR4.     
It has been suggested that Tlr4
-/-
 HSCs have a competitive advantage compared to 
WT HSCs in transplantation assays (Ichii et al., 2010).  We found that myeloid 
reconstitution was equivalent in WT and Tlr4
-/-
 HSCs when competed in the same mouse, 
but Tlr4
-/-
 HSCs gave rise to more B-lineage cells over 16 weeks, which may explain the 
previous group’s findings.  Although our reverse chimera experiments indicated that 
NOD-like receptor signaling in radio-resistant cells is important for promoting 
extramedullary hematopoiesis, they did not rule out the possibility that NOD1 or NOD2 
may play a role within HSCs.  To determine whether NLR signaling is important within 
HSCs, one could mix and transplant equal numbers of hematopoietic cells from congenic 
Ripk2
-/-
 and WT mice and measure peripheral blood chimerism over 16 weeks.  If NLR 
signaling affects HSC function, this could have implications for therapies in which 
pharmacological agents used to elicit responses in HSCs are purified from bacteria and 




 In total, the results presented in this thesis expand our knowledge of how PRR 
signaling is controlled and provide insight into how PRRs influence the activity of HSCs.  
Given our discoveries that NLRs and TLRs are important for expanding extramedullary 
HSCs in the context of infection and that this phenomenon is dependent on G-CSF, it is 
possible many of the genes identified as regulators of NOD2/NF-κB signaling in our 
genome-wide screen may influence HSC mobilization in concert with G-CSF.  Thus, 
regulators of NOD2/NF-κB might serve as useful targets to improve mobilization 
therapies.  While our findings establish a framework to understand the biology of PRR 
signaling, further investigation is required to understand their contribution to autoimmune 
disorders and to define mechanisms underlying the regulation of HSCs and their niche(s) 
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